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PREFACE
The present thesis is based on studies performed at the Danish Cancer Society, Department of 
Molecular Cancer Biology. 
The aim of this present study was to establish a translocation biosensor system that could be used 
to monitor S100A4:target protein interactions in living cells. Additionally, the S100A4 binding 
interface on the protein targets p53 and non-muscle myosin heavy chain IIA was investigated by 
in vitro experiments to support cloning engineering of vectors to be used in the in vivo transloca-
tion assay.
Research was carried out in the period from August 2006 until September 2007 and this project 
was supported by a scholarship from the Danish Cancer Society.
Roskilde, Denmark, November 2007
Henrik Devitt Møller
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ABSTRACT
The S100A4 protein has been found involved in the metastatic process of various aggressive can-
cer types. Tumors with highly up-regulated S100A4 is generally associated with bad prognosis and 
significant reduced survival chances. Several reports state that S100A4 promote cellular motility 
and invasion, probably through interactions with intracellular proteins, such as the non-muscle 
myosin heavy chain IIA (MHC-IIA), influencing the cytoskeleton dynamics (Alexandrova et al., 
2000; Chen et al., 2001). Moreover, S100A4 has also extracellular functions, promoting break-
down of extracellular matrix components, supporting cell progression (Bjørnland et al., 1999; 
Semov et al., 2005).
In this study, we wanted to develop a protein translocation system, using fluorescence biosensors 
of S100A4 and identified S100A4 targets in vitro, to monitor S100A4 interactions in vivo. Ad-
ditionally, we would examine the existence of a possible common binding interface on different 
S100A4 intracellular targets including p53, MHC-IIA and liprin b1. 
We found that S100A4 had affinity for the blue fluorescence fusion protein (RevM10BL-BFP), 
used as biosensor for S100A4 target protein fragments, unfortunately creating to high signal back-
ground for practical use of this established protein translocation system. Nevertheless, we found 
evidence that supports the existence of small common S100A4 binding interface (the amino acid 
residues SLKS/N
K/D), which is involved in S100A4 binding of p53 and MHC-IIA protein fragments 
in vitro.
Abstract
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RESUMÉ
Man har fundet ud af, at S100A4 proteinet er involveret i metastase processer i forskellige aggres-
sive cancer typer. Højt opreguleret S100A4 i tumorer er generelt forbundet med dårlige prognoser 
og signifikant reducerede overlevelseschancer. Adskillige rapporter angiver, at S100A4 fremmer 
cellemobilitet og invasion, sandsynligvis gennem interaktion med intracellulære proteiner, såsom 
den tunge kæde i ikke-muskular myosin type IIA (MHC-IIA), der påvirker cytoskelettets dy-
namik (Alexandrova et al., 2000; Chen et al., 2001). Ydermere har S100A4 også ekstracellulære 
funktioner, indbefattende indflydelse i nedbrydning af ekstracellulære matrix komponenter, der 
promoverer cellebevægelse. 
I dette studie ville vi udvikle et protein translokerings system, hvor vi ville anvende fluorescerende 
biosensorer for S100A4 samt identificeret S100A4 interaktionspartnere in vitro, for at observere 
S100A4 interaktioner in vivo. Desuden ville vi undersøge eksistensen af et muligt fælles bind-
ingssted på forskellige S100A4 intracellulære protein partnere, heraf p53, MHC-IIA og liprin b1.
Vi fandt, at S100A4 havde affinitet for det blå fluorescerende fusionsprotein (RevM10BL-BFP), 
anvendt som biosensor for S100A4 protein partner fragmenter, som uheldigvis forsagede for høj 
baggrundssignal for praktisk anvendelse af dette etablerede protein translokation system. Ikke 
desto mindre fandt vi udfra in vitro eksperimenter, indikation på tilstedeværelsen af et lille fælles 
S100A4 bindingssted (aminosyrerne SLKS/N
K/D), der er involveret i S100A4 binding af p53 og 
MHC-IIA protein fragmenter.
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INTRODUCTION
The potential risk for developing cancer is generally increasing in many developed countries. 
Even though the treatment of various cancer types has improved over the last decades, the chances 
of recovery from highly aggressive dividing tumors are still poor.
Tumorigenesis can be initialized through epigenetic alterations or after collections of several mu-
tations in cellular DNA, typically in oncogenes and tumor suppressor genes (Karpinets & Foy 
2005). These critical events can lead to abnormal cells with a potential risk for unrestrained cell 
proliferation that can give rise to a primary tumor. Accompanied by angiogenesis, tumor growth 
can continue and tumor cells can start to invade surrounding tissues through degradation of the 
extracellular matrix (ECM). For cancer patients this is particular devastating because of high pos-
sibility for cell metastasis, in which tumor cells detach from the primary site and form secondary 
tumors, significantly reducing chances for survival (Wyke 2000; Crawford & Hunter 2006).
During the recent years different molecular factors have been found involved in the metastatic 
process. Among them is the S100A4 protein, which has been shown to have an important impact 
on metastasis formation in different transgenic mice models. This became clear after grafting 
S100A4-/- mice with highly metastatic CSML-100 cells. These CSML-100 cells showed impaired 
tumor-stroma formation, resolving in longer time-periods before tumors could be observed. More 
importantly, the tumors did not developed metastases in contrast to xenografts of CSML-100 cells 
implanted in wild type mice (Grum-Schwensen et al., 2005). Additionally, expression of S100A4 
cDNA in breast cancer (MCF-7 cells) or rat mammary cells (Rama 37 cells) also promoted tumor 
progression and cellular changes toward more malignant cell phenotypes (Grigorian et al., 1996; 
Lloyd et al., 1998). Whereas, expression of antisense S100A4 RNA in CSML-100 tumor or Lewis 
lung carcinoma cells suppressed the cells invasiveness and the cells motility in vitro (Grigorian et 
al., 1993; Takenaga et al., 1997b; Bjørnland et al., 1999). 
Although the understanding of the pathobiology of S100A4 is far from completed in vivo, S100A4 
has been suggested to promote cellular motility through interactions with intercellular proteins 
(Alexandrova et al., 2000; Chen et al., 2001). Reports show that S100A4 accumulates with non-
muscle myosin heavy chain IIA (MHC-IIA) and liprin b1 at the leading edge of a migrating cell’s 
forward protrusions (Kim & Helfman 2003; Li & Bresnick 2006). 
S100A4 is also known as an extracellular secreted protein that exerts cytokine-like functions. 
Introduction
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Based on transgenic animals and in vitro studies, extracellular multimeric S100A4 was suggested 
as an angiogenic factor (Ambartsumian et al., 2001+2005). The pro-metastatic action of S100A4 
has further been addressed to its interaction with the endothelial plasminogen co-receptor annexin 
II that seems to influence modulation of the ECM (Semov et al., 2005). Additionally, S100A4 also 
functions as a signal transducer (Novitskaya et al., 2000; Pedersen et al., 2004; Kiryushko et al., 
2006; Schneider et al., 2007). S100A4 has stimulated up-regulation of matrix metalloproteinase 
13 (MMP-13) (Yammani et al., 2006) and other MMPs; 1, 3, and 9 (Senolt et al., 2006b), signi-
fying an influential S100A4 role on ECM degradation and the pool balance between MMPs and 
TIMPs (tissue inhibitor of metalloproteinases) (Bjørnland et al., 1999; Schmidt-Hansen et al., 
2004a+b; Saleem et al., 2006).
Up-regulation of S100A4 in cancer is generally associated with bad prognosis, which unfortunate-
ly is the situation in many human cancer types including; bladder, gall bladder, breast, colorectal, 
prostata, gastric, esophageal, non-small-cell lung, medulloblastoma, pancreatic and hepato-cel-
lular cancer (Rudland et al., 2000; Pedersen et al., 2002; Lee et al., 2004; review Helfman et al., 
2005). Different S100A4 status in primary tumors from patients with invasive operable stage I and 
II breast cancer, revealed a statistical significant difference in survival rate after a 19 year period. 
Of patients, having tumors with a S100A4-negative status, 80 % had survived versus only 11% of 
patients with S100A4-positive tumors (Rudland et al., 2006). 
Medically, the metastatic potential of tumors cannot be predicted sufficiently by histological grade 
analysis or simply by tumor size, thus better molecular markers are needed for guidance of medi-
cal treatment. The S100A4 protein might be a possible candidate for early determination of meta-
static potential of cancer as well as a cancer therapeutic target (van der Poel 2006; Lee et al., 2004; 
Helfman et al., 2005; Saleem et al., 2005+2006; Bøe & Hovig 2006). 
Finding a drug that could inhibit the S100A4 intracellular and extracellular activities to abolish 
tumor progression would be a great achievement. Extracellular multimer S100A4 is known to 
induce neurite outgrowth (Novitskaya et al., 2000; Kiryushko et al., 2006) and recently short 
peptides were found able to inhibit this S100A4 induction (Jörg Klingelhöfer, unpublished data). 
This finding indicates that targeting S100A4 functions by small molecular drugs will be a promis-
ing strategy to possible inhibit its pro-metastatic ability. Interestingly, one of the found inhibiting 
peptides resembles a part of the known binding domains of many intracellular S100A4 protein 
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targets (Jörg Klingelhöfer, unpublished data), including MHC-IIA (Kriajevska et al., 1998), liprin 
b1 (Kriajevska et al., 2002) as well as the tumor suppressor p53 (Grigorian et al., 2001).
Previously, Knauer and co-workers developed a protein translocation biosensor system for living 
cells. Composed of two different fluorescence fusion proteins; one that shuttles between the nu-
cleus and the cytoplasma and the other fixated to the nucleus/nucleolus, enabled protein-interac-
tions studies monitored by fluorescent microscopy (Knauer et al., 2005). 
The goal of this project was to adopt and convert this protein translocation system to investigate 
S100A4 interactions with known S100A4 targets. Establishing this screening system in living 
cells will provide important knowledge about a possible common binding domain for S100A4 on 
its protein targets. Additionally, it will be a valuable tool to evaluate whether inhibiting peptides 
of neurite-outgrowth might also have intracellular effects on S100A4:target-protein interactions in 
situ, which potentially could lead to a functional anti-metastatic S100A4 drug.
BACKGROUND THEORY
The S100 protein family
The first time the “S100” name appeared was in 1965, when Moore isolated the S100 protein 
in a bovine brain subcellular fraction. The protein was collected in a 100% ammonium sulphate 
solution, hence the name S100 (Sulphate 100%) (Moore 1965). Later on, this fraction was shown 
to consist of predominant amounts of two S100 proteins; S100A1 and S100B (review Zimmer 
et al., 1995). The S100A4 was discovered in 1987 by Jackson-Grusby and his team. They de-
scribed presence of S100A4 mRNA (then designated 18A2 and also known as mts1, pEL-98, 
p9Ka, CAPL, calvasculin, Fsp1) in several tissues of mice (Jackson-Grusby et al., 1987). A few 
years later, Ebralidze et al. suggested S100A4 involvement in cell metastasis after discovering 
a correlation between S100A4 mRNA levels and the metastatic potentials of several cancer cell 
lines (Ebralidze et al., 1989).
Today, 24 members of the S100 proteins are known (Marenholz et al., 2006) and they are all de-
scribed as low molecular weight proteins ranging in sizes from 9 to 13 kDa (Table 1), including 
the 11.6 kDa S100A4 protein (Schäfer et al., 1995; Barraclough 1998; Marenholz et al., 2006; 
review Yao et al., 2007). 
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Name* Synonyms Potential functions
S100A1 S100A, S100α Regulates cell growth, tubulin, energy metabolism, contractions, SR release of calcium.
S100A2 S100L, CaN19 Affect actin-cytoskeleton dynamic via tropomyosin interaction
S100A3 S100E
S100A4
Mts1, metastasin, calvas-
culin, calcium placental 
protein (CAPL), p9Ka, 42A, 
18A2
Modulates cell motility, structure, cytoskeleton dynamics, growth, intracellular calcium levels, the 
extracellular matrix and various proteins (e.g. p53 and non-muscle myosin heavy chain IIA). Has 
cytokine-like functions, stimulating angiogenesis, neurite outgrowth and functions as a signalling 
molecule
S100A5 S100D
S100A6
Calcyclin (CACY), 2A9, 
PRA, CaBP 5B10
Regulate cell growth, actomyosin ATPase activity, cell cycle and intracellular signal transduction
S100A7
Psoriasin 1 (PSOR1), 
S100A7c
Up regulated at lesions and when cells lack ECM or growth factors – role unknown
S100A7A S100A15, S100A7L1
S100A7L2 S100A7b
S100A7P1 S100A7L3, S100A7d
S100A7P2 S100A7L4, S100A7e
S100A8
Calgranulin A (CAGA), 
CGLA, MRP-8, P8, MAC 
387, B8Ag, L1Ag, CP-10, 
MIF, NIF
Regulate cell growth and kinase activity. Modulate intermediate fi laments and repair of wounds
S100A9
Calgranulin B (CAGB), 
CGLB, CFAg, MRP-14, 
P14, MAC 387, B8Ag, 
L1Ag, CP-10, MIF, NIF
Similar functions as S100A8
S100A10
Ca[1], p11, p10, 42C, Cal-
pactin 1, annexin II ligand 
(ANX2LG)
Regulate neurotransmitter release, stimulate annexin II and F-actin to membranes and process anti-
infl ammatory inhibition of phospholipase A2
S100A11 Calgizzarin, S100C Inhibits tumor cell motility, actomyosin ATPase activity and regulates annexin I
S100A11P S100A14
S100A12
Calgranulin C (CAGC), 
CAAF1, CGRP, p6, EN-
RAGE
Modulate  interactions of cytoskeleton elements with membranes, proinfl ammatory and neurite exten-
sion activity 
S100A13 Promote release of fi broblast growth factors
S100A14 S100A15, BCMP84
S100A16
S100F, DT1P1A7, 
MGC17528
S100B S100Β, NEF
Regulate cell growth/differentiation, contraction, cell structure, microtubules assembly, p53 transcrip-
tion activation and energy metabolism. Involved in intracellular signal transduction, neurite outgrowth, 
memory and learning. 
S100G
Calbindin 3 (CALB3), 
ICaBP, CaBP9K, CABP1, 
Calbindin-D9k
Regulate calcium homeostasis
S100P Stimulate cell survival and proliferation
S100Z S100-zeta
Table 1. The S100 proteins. The family of the S100 proteins are presented with suggested functions and synonyms 
after the new S100 nomenclature (Marenholz et al., 2006). Modified after Schäfer et al., 1995 and reviews by Zimmer 
et al., 1995; Donato 1999+2003; Emberly et al., 2004; Marensholz et al., 2004; Santamaria-Kisiel et al., 2006.
Several cellular processes are regulated and affected by S100 proteins, such as calcium homeosta-
sis, cell motility, enzyme activity, differentiation, growth, immune response, signal transduction, 
morphology and the dynamics of cytoskeleton components (reviews by Zimmer et al., 1995; Do-
nato 1999+2003; Emberly et al., 2004). The expression patterns of S100 genes varies remarkably 
within different cell types and in between the S100 protein pool. Not all S100 proteins are found 
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in all cell types, for instance is S100A4 found in the lungs and spleen but not in the brain or testes 
in which S100B is found (reviews by Zimmer et al., 1995; Donato 1999; Yao et al., 2007). Dis-
tinct sub-cellular localization patterns of the S100 proteins are also reported. S100A4 and S100A1 
have been found predominately in the cytosol, associated with the sarcoplasmic reticulum, while 
S100A2 and S100A6 has been located primarily to the cell nucleus (Mandinova et al., 1998; Orre 
et al., 2007). Moreover, the promoter region of the S100 genes are far from similar (Schäfer et 
al., 1995) just as S100 protein variations are detected within the cell cycle, pointing out that S100 
members might have specialised functions determined by the expression, cell type and the micro-
environment (Jackson-Grusby et al., 1987; reviews by Donato 1999; Emberly et al., 2004). 
The S100 protein structure
The structure of S100 proteins are conserved (Fig. 1) and they have 25-65 % homology in their 
amino acid sequences (Schäfer et al., 1995; review Marensholz et al., 2004). In general, they all 
exist as highly stable anti-parallel packed homodimers though some also form heterodimers (e.g. 
S100A1/S100A4) (review Bhattacharya et al., 2004; Wang et al., 2005). Typically, a S100 mono-
mer comprises four alpha helixes (I-IV) that form a pair of EF-hand calcium binding domains (Fig. 
1B). These are connected through a hinge region and at the C-terminal end, normally is found an 
extended flexible tail of variable amino acid residues (Schäfer et al., 1995; Vallely et al., 2002).
       S100A42           S100B2
B
III
II
I
IV
IV ’
I’
II ’
III’
A
N-term Ca2+-binding loop       C-term Ca2+-binding loop
N              C
I          II      III           IV      tail
             “hinge”-region
Ca2+ Ca2+
Fig. 1. Tertiary and secondary structure of S100 proteins. (A) Displays the ribbon models of the S100A4 and the 
S100B calcium bound homodimers (Tarabykina et al., 2001; Bhattacharya et al., 2004). (B) Displays the secondary 
structure of the S100 protein. The structure consists of four helixes (I-IV), two calcium binding domains, a linker 
“hinge” region connecting the two EF-hand motifs and lastly an extended C-terminal tail (modified after Tarabykina 
et al., 2007).
For S100 proteins, the sensitivity for calcium ions is general within the range of 0.1-10 µM. The 
Ca2+-binding is pH dependent, generally implicating no Ca2+-binding below pH 6.0 while the 
calcium binding sites are fully loaded above pH 8.3 (dependent on calcium ions available and 
the presence of other calcium-binding proteins) (review Zimmer et al., 1995). The EF-hand loop 
nearest the N-terminal in a S100 protein harbors 14 amino acid residues and is characterized as a 
Background theory
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pseudo-EF-hand. This site has about 100 times lower calcium affinity (Kd~200-500 mM) com-
pared to the EF hand loop closest to the C-terminal (Kd~10-50 mM) (reviews by Zimmer et al., 
1995; Emberly et al., 2004; Yao et al., 2007). 
A generally feature for the S100 family proteins, is a significant conformational change restricted 
by the calcium concentration. Going from the S100 apo-state homodimer form to four coordinated 
Ca2+-ions leads to displacement of bulky hydrophobic groups on the S100 protein surface, nor-
mally hidden within the protein (Fig. 2). This rearrangement is believed to provide important S100 
interacting specification for molecular targets, govern by hydrophobic interactions. An equally 
essential feature for S100 protein interactions is the ability to complement polar and charged 
groups (review Donato 1999). Mutated forms of S100A4 have revealed that the extreme variable 
C-terminal (last 15 amino acid residues) and the Ca2+-binding ability is necessary for keeping the 
integrity of the majority of S100A4 functions (Zhang et al., 2005b).
Fig. 2. The S100A4 structure. The ribbon diagram shows, based on NMR solution structures, the S100A4 homodim-
er in the apo-state (left) and the calcium-bound form (right). Particularly conformational changes upon Ca2+ binding 
(shown as red spheres) takes place within the hinge region and helix 3 (shown in orange), resulting in a more open, 
voluminous dimer revealing hydrophobic residues at the protein surface (Garrett et al., 2006).
The S100A4 protein
S100A4 has no known enzymatic activity and its functions rely on intracellular as well as extra-
cellular protein interactions (Helfman et al., 2005). S100A4 expression has been found widely 
among different cell types such as lung, spleen, heart, bone marrow, nerve and skeletal muscle 
(reviews by Zimmer et al., 1995; Donato 1999; Yao et al., 2007). Non-invasive cells have in com-
parison to highly motile cells, such as T-lymphocytes and macrophages, lower S100A4 expression 
levels (Takenaga et al., 1997a; Klingelhöfer et al., 1997+2007). Since 1989, substantial reports 
have verified a link between S100A4 status and the metastatic capabilities of cells (Lakshmi et al., 
1993; Grigorian et al., 1993+1996; Takenaga et al., 1997b; Lloyd et al., 1998; Xue et al., 2003; 
Ambartsumian et al., 2005; Grum-Schwensen et al., 2005; Helfman et al., 2005; Li & Bresnick 
2006; Senolt et al., 2006a; Tarabykina et al., 2007). S100A4 seems not to be tumorigenic itself, 
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since overexpression of S100A4 in transgenic mice did not result in tumor development (reviews 
by Takenaga et al., 1997b; Emberley et al., 2004; Li & Bresnick 2006) however long term ex-
pression in mice gave tumors in late stages of life (Ambartsumian et al., 2005). More likely, 
S100A4 potentially acts as a metastatic inducer in a given tumorigenic background (Helfman et 
al., 2005).
Early on, it was suggested that S100A4 participates in regulation of the cytoskeleton dynamics 
(Kriajevska et al., 1994; Takenaga et al., 1994) and by this way confer properties to the cells, 
like motility and metastatic spread (Lakshmi et al., 1993; Li and Bresnick 2006; Tarabykina et 
al., 2007). Inside the cell many different proteins have been announced as subjects for S100A4 
modulation (Table 2). 
Potential S100A4 
intracellular targets Function of target protein Method Suggested S100A4 function References
Actin fi laments
Thin actin-fi laments (F-actin) 
constitute the microfi laments in the 
cytoskeleton and provide strength in 
muscle cells.
IF, OP, 
WB
Decrease F-actin levels through unknown signal 
pathways and could be an actin crosslinker.
Watanabe et al., 1993; Gibbs 
et al., 1994; Mandinova et al., 
1998; Belot et al., 2002; Brisset 
et al., 2007
CCN3
CCN3 regulates intracellular calcium 
levels and promotes extracellular 
calcium uptake. 
AC, 
Y2H
Interferes with S100A4 ability to bind calcium 
ions and function as a calcium buffer. 
Li et al., 2002; review Lombet et 
al., 2003
Liprin β1
Affect the LAR transmembrane  
signalling that is implicated in remod-
elling of the cytoskeleton, cell-cell 
and cell-focal adhesion.
IF, IP, 
MS
Inhibit liprin alfa1-beta1 complex formation and 
phosphorylation of liprin-b1 by PKC and CK2. 
LAR signalling is promoted indirectly.
Kriajevska et al., 2002; review 
Tarabykina et al., 2007
Methionine 
Aminopeptidase 2
Regulates protein synthesis and re-
move the initiator methionine residues 
from nascent peptides.
AC, IP, 
Y2H
Regulates the enzyme activity through changing 
its localization. Endo et al., 2002
Non-muscle 
myosin heavy chain 
IIA
Part of the cytoskeleton AC, IP, OP, WB
Modulate myosin fi lament formations. Inhibit 
protein kinase C phosphorylation. 
Kriajevska et al., 1998; Murakami 
et al., 2000; Chen et al., 2001; 
Kim & Helfman 2003;  Li et al., 
2003; Dulyaninova et al., 2005; 
Zhang et al., 2005a+b 
Non-muscle 
Tropomyosin
Part of the cytoskeleton. Binds actin-
fi laments and works as a crosslinker 
between fi laments.
AC, IF
Modulation of actomyosin ATPase activity. Infl u-
ence the cytoskeleton by regulating tropomyosin-
actin association.
Takenaga et al., 1994
p53 Tumor suppressor, transcription factor and controls apoptosis.
AC, IP, 
OP
Stimulate p53-dependent cell growth arrest and 
apoptosis. Protect against denaturation, tetrameri-
zation and aggregation. Inhibit p53-dependent 
transcription activity and p53 function. Inhibits 
p53 phosphorylation.
Grigorian et al., 2001; Chen et al., 
2001; Fernandez-Fernandez et al., 
2005; Wilder et al., 2006
S100A1
Impair activation of cell migration and 
promotes MHC-IIA assembly through 
S100A4 inhibition.
ESI-FT-
ICR, FS, 
Y2H
Negative modulator of S100A4 activity. Have 
similar Kass and Kdiss values as the S100A4 dimer.
Tarabykina et al., 2000; Wang et 
al., 2000+2005
Tubulin Alfa and beta-tubulin heterodimers forms the microtubule. Affect tubulin polymerisation state. Lakshmi et al., 1993 
Table 2. Table of S100A4 intracellular protein targets, functions and suggested S100A4 modulations.
Experimental methods for S100A4 interaction detections (reported in references) are presented in short abbrevia-
tions: AC=Affinity column Chromatography, ESI-FTICR=ElectroSpray–Ionization Fourier Transform Ion Cy-
clotron Resonance mass spectrometry, FS=Fluorescence Spectroscopy, IF=ImmunoFluoresence co-localization, 
IP=ImmunoPrecipitation, MS=Mass Spectrometry, NMR=Nuclear Magnetic Resonance spectroscopy, OP=Optical 
Biosensor, Y2H=Yeast Two-Hybrid system, WB=Far-Western Blotting. Table modified after references and reviews 
by Donato 1999+2003; Emberly et al., 2004; Tarabykina et al., 2007.
Background theory
14
Establisment of a Translocation Biosensor to monitor S100A4:Target Protein Interactions in living cells
S100A4 has been found co-localized with non-muscle tropomyosin isoform 2 (Takenaga et al., 
1994), alpha-smooth muscle actin in stress fibres (Mandinova et al., 1998; Brisset et al., 2007) 
and bundles of F-actin filaments in vitro (Watanabe et al., 1993; Gibbs et al., 1994). Additionally, 
S100A4 expression appears to influence tubulin polymerisation in B16 melanoma cells (Lakshmi 
et al., 1993). Later in vitro studies have implied that these cytoskeleton components do not interact 
directly with S100A4 (Chen et al., 2001), but might be affected indirectly by S100A4. 
S100A4 interactions to intracellular target proteins includes among others; liprin b1 (Kriajevska 
et al., 2002), non-muscle myosin heavy chain IIA (MHC-IIA) (Kriajevska et al., 1998; Murakami 
et al., 2000; Chen et al., 2001; Kim & Helfman 2003; Dulyaninova et al., 2005; Zhang et al., 
2005a+b) and the tumor suppressor p53 (Chen et al., 2001; Grigorian et al., 2001; Fernandez-
Fernandez et al., 2005). 
S100A4 was shown to facilitate disassembly of myosin filaments in vivo. This could contribute 
to significant structural rearrangement of the cytoskeleton, providing a plausible way for promot-
ing cell polarization and cell motility by S100A4 (Kriajevska et al., 2000; Li & Bresnick 2006). 
In addition, interaction with liprin b1 could perhaps promote release from cell adhesion enabling 
migration (Kriajevska et al., 2000+2002; review Tarabykina et al., 2007). Interestingly, p53 might 
also have a role in cell migration and morphology. Alexandrova et al. have shown p53-/- mice 
fibroblasts display increased migratory properties. A tetracycline-regulated expression of human 
exogenous p53 in p53-/- mice fibroblasts, showed decreased cell migration and reduced changes of 
morphology in vitro (Alexandrova et al., 2000). This function could perhaps be a counterpart for 
S100A4-p53 interaction, inhibiting the possible p53 effect on motility. The concrete role of p53 
interaction is however still under speculations and is discussed later on. 
S100A4, which do not carry any classical secretion signals, is secreted from cells through an un-
known secretion pathway (reviews by Donato 2003; Helfman et al., 2005). Extracellular S100A4 
interacts among others with Ca-ATPase (Table 3). This interaction subsequently leads to lower 
intracellular Ca2+ levels (Dukhanin et al., 2001), indicating a possible role in controlling calcium 
homeostasis. 
Background theory
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Potential S100A4 extra-
cellular targets Function of target protein Method Suggested S100A4 function References
Annexin II
An intracellular plasminogen co-receptor that 
is exposed on the extracellular membrane 
surface in activated endothelial and some 
tumor cells.
IP, NMR, 
WB
Accelerate plasminogen conversion to plasmin. 
Infl uence indirectly ECM remodelling and 
facilitates angiogenesis.
Semov et al., 2005 
Ca-ATPase (p37) Plasma membrane protein that active trans-ports Ca2+ ions out of the cell. AC
Mediates activation of Ca-ATPase at high 
calcium levels, leading to lower intracellular 
Ca2+ levels.
Dukhanina et al., 1997; 
Dukhanin et al., 2001
Heparan sulfate 
proteo glycan
Receptor abundant in the extracellular matrix 
and on cell membranes. FS, WB
Possible receptor or co-receptor for S100A4-
induced neurite outgrowth and activated S100A4 
signaling.
Kiryushko et al., 2006
RAGE
Receptor for advanced glycation end products 
(RAGE) plays an important role in diabetes, 
Alzheimer’s disesase, infl ammation and 
cancer.
AC, IP
Possible receptor or co-receptor for S100A4. Ac-
tivates RAGE signalling pathway (ERK1/2) in 
chondrocytes. Induce RAGE-mediated increase 
of MMP-13 production.
Yammani et al., 2006
Table 3. Potential S100A4 extracellular protein targets, functions and suggested S100A4 modulations. 
Methods for S100A4 interaction detections reported in references are presented in short abbreviations presented 
in the table: AC=Affinity column Chromatography, ESI-FTICR=ElectroSpray –Ionization Fourier Transform Ion 
Cyclotron Resonance mass spectrometry, FS=Fluorescence Spectroscopy, IF=ImmunoFluoresence co-localization, 
IP=ImmunoPrecipitation, MS=Mass Spectrometry, NMR=Nuclear Magnetic Resonance spectroscopy, OP=Optical 
Biosensor, Y2H=Yeast Two-Hybrid system, WB=Far-Western Blotting. Table modified after references and reviews 
by Donato 1999+2003; Emberly et al., 2004; Tarabykina et al., 2007.
The inflammatory associated multi-ligand receptor of the immunoglobulin superfamily RAGE has 
been proposed as a possible receptor for extracellular multimer S100A4. Experiments have indi-
cated that S100A4 could induce the RAGE-mediated signalling cascade, resolving in up-regulation 
of matrix metalloproteinase 13 (Yammani et al., 2006). However, others do not find a concrete link 
between S100A4 and RAGE (Kiryushko et al., 2006). Recently, the S100B protein, that induces 
RAGE (Huttunen et al., 2000), was reported in tetrameric and octameric structures. Tetramers 
bound and induced the RAGE signal pathway and was suggested to promote RAGE dimerisation 
that triggers RAGE activation (Ostendorp et al., 2007). The active cytokine form of S100A4 could 
have a similar extracellular oligomer structure, as S100B, perhaps stimulating signal transduction 
through RAGE or another receptor/co-receptors (Kiryushko et al., 2006).
Summarized, the potential S100A4 functions and targets are presented in figure 3 for illustration 
of its vast multiplicity.
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Liprin β1
Liprin α1
Other functions:
Secretion ?
Tubulin
Tropomyosin
Methionine 
Aminopeptidase 2
Fig. 3. Overview model on S100A4 potential functions. On various levels S100A4 modulates different intracellular 
proteins through protein interactions. For instance, proteins are affected through translocation, phosphorylation and 
oligomerisation inhibition (e.g. liprin b1, methinionine aminopeptidase 2 and p53). S100A4 also influence proteins 
functions as effects gene transcription factors (e.g. p53), intracellular signalling (e.g. liprin b1) and general their pro-
tein activity. Intracellular S100A4 modulates the cytoskeleton dynamics (actin, MHC-IIA, non-muscle tropomyosin 
and tubulin) that possibly affects the cell motility and morphology. Negative S100A4 modulators such as CCN3 and 
S100A1, might work as buffers to control and regulate S100A4 functions. As illustrated, the secretion of S100A4 is 
still not clear. The extracellular roles of the bioactive multimer S100A4 includes among many, neurite outgrowth, an-
giogenesis, extracellular matrix remodelling, calcium regulation and release from the endoplasmatic reticulum (ER) 
and signal transduction through the surface receptor RAGE or yet an unknown receptor(s).
EXPERIMENTAL INTRODUCTION
Protein interactions are usually tested by techniques such as Far-Western blotting, ELISA, pull-
down experiments, Biacore or Nuclear Magnetic Resonance (NMR). These in vitro techniques 
are commonly used but correspond far from the genuine cell environment in vivo. Other methods 
have been developed recently to accommodate this problem, such as the yeast two-hybrid system, 
protein microarrays and protein translocation assays (Paulmurugan et al., 2002; Hu & Kerppola 
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2003; Pagliaro et al., 2004 and reference within; Knauer et al., 2005; Seitz et al., 2006). To evalu-
ate effects of molecular drugs most realistically for later medical use, the complexity of living 
cells must be taken into account. 
The aim of this project is to employ and convert the cell-based translocation biosensor assay, 
developed by Knauer et al., to obtain a system, in which S100A4 protein interactions could be 
monitored in vivo. This project focuses on S100A4 interactions with p53, MHC-IIA and to some 
extent the liprin b1, which all contains a putative common S100A4 binding site. 
The translocation biosensor system
The original described biosensor by Knauer and colleagues is composed of two different fusion 
proteins encoded by different vectors (Knauer et al., 2005). The first vector is the shuttle biosensor 
(Fig. 4) encoding cDNA of the interacting protein “prey” (e.g. S100A4). Furthermore, it encodes 
for the green fluorescent protein (GFP) from jellyfish Aequorea victoria (Inouye & Tsuji 1994) 
and the glutathione-S-transferase protein (GST). Supplemented, the fused sequences is flanked by 
a nuclear import signal (NLS) at the N-terminal and a nuclear export signal (NES) at the C-termi-
nal. The NLS and NES confer the prey-fusion protein the ability to shuttle between the cytoplasm 
and the nucleus (review Nigg 1997). Expression of the shuttle vector in a cell will, because of a 
stronger nuclear export signal, predominately locate the shuttle fusion-protein in the cytoplasm 
(Knauer et al., 2005). 
PreyGFP GST
HIV-1 Rev NES:
LQLPPLERLTL
SV40 NLS:
PPKKKRKVEDP
Fig. 4. The shuttle vector. The shuttle biosensor encoding the GFP-GST-prey fusion protein, flanked by the weak 
SV40 T-antigen nuclear localization signal (NLS) at the N-terminal and the strong HIV-1 Rev nuclear export signal 
(NES) after the protein-prey C-terminal (modified after Knauer et al., 2005).
The second vector is the nucleolus fixated BFP-bait biosensor (Fig. 5). This encodes for the blue 
fluorescent protein (BFP) fused with a NES-deficient HIV-1 RevM10BL sequence and the bait 
protein (e.g. p53, liprin b1 or MHC-IIA). The RevM10BL leads to accumulation of the bait protein 
in the nucleolis of the cell (Stauber et al., 1998). 
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BFPNABait
including M10BL:
LQLPPDLRLEDLPTL
Fig. 5. The BFP-bait vector. Coding for a fusion protein; including a blue fluorescence protein (BFP), a separating 
linking sequence (NA) as well as an encoding cDNA sequence of the bait/target protein. Within the NA sequence is 
the M10BL that is NES-deficient and locates the fusion protein to nucleoli (modified after Knauer et al., 2005).
The distinguishable cytoplasmic and nucleus cell compartments make the translocation assay use-
ful for detection of protein complexes, between the bait and the prey-fusion proteins by fluores-
cence microscopy (Fig. 6). Protein interaction will lead to nucleus/nucleoli accumulation of the 
shuttle protein, because of binding to the protein target. Otherwise, fusion proteins that do not 
interact will be monitored to their individual cell compartments respectively.
GFP: shuttling protein
BFP: nucle(ol)ar fixation
 no interaction  interaction
BFPNA
GFP GST Prey
Target
Rev NESSV40-NLS
Interaction domain 1
Interaction domain 2
weak strong
 
Fig. 6. Model of the biosensor translocation system to monitor in vivo protein:protein interactions. Due to a 
strong nuclear export signal (Rev NES) and the weak nuclear localization signal (SV40-NLS), the shuttle GFP biosen-
sor predominantly locates to the cytoplasm. Interaction between the protein-prey and the protein-target translocates 
the GFP signal to the nucleoli, which can be easily detected by fluorescent microscopy.
For proper use, the establishment of the in vivo protein biosensor read out system should fulfil 
several criterias. First of all, the system should be reliable in expression of fusion proteins in cells. 
Secondly, a high signal to noise ratio is necessary to insure specific protein interactions, meaning 
that the shuttle proteins should predominantly localize to the cytoplasm, just as the target-proteins 
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to the nucleolis. Thirdly, interaction between prey and target should not be affected by the differ-
ent fluorescent proteins or other elements of the fusion constructs and finally, the system should be 
reversible and robust for drug screening.
The developed biosensor system prior this project
The original biosensor vectors, kindly provided by Knauer and her team, consisted of the Max-
RevM10BL-BFP vector and the NLS-GFP-GST-Jun-NES shuttle vector (Knauer et al., 2005). 
Using directed PCR-cloning strategy, the sequence of Jun in the shuttle vector was replaced by 
S100A4 cDNA (Scheme 1). 
EGFP + NES cloning
S100A4 shuttle cloning
Empty vector Cloning
EGFP GST S100A4
pS510-EGFPGST-NES-S100A4 (44)
EcoRV ApaIKpnINheI XhoI
NheI NotI
GFP GST S100A4
KpnIKpnI XhoI
pS-GFPGST-S100A4-NES (03)
S100A4 shuttle vectors
GFP GST
pS-GFPGST (15)
KpnINheI
GFP GST Jun
BamHI KpnINheI KpnI NotI XhoI EcoRI
p3-NLS-GFPGST-Jun-NES (02)
BFPNAMyo
pN-MHC-IIA-BFP (08)
KpnI KpnI
492 bp
pN-p53-BFP (04)p53
177 bp
KpnI KpnI
S100A4 pN-S100A4-BFP (06)
KpnI
297 bp
BFPNApN-BFP (14)
KpnI EcoRI EcoRI XbaI
Lip pN-Liprin-BFP (09)
KpnI
192 bp
Βait-Vectors (targets in N-terminal) 
BFPNAMax
HindIII NheIKpnI KpnI HindIII EcoRI EcoRI XbaI
pc3-Max-RevM10BL-BFP-gcs (01)
Cloning of 
BFP-control 
Cloning of 
protein targets
  
Scheme 1. Biosensor vectors. Cloned vectors manufactured by Jörg Klingelhöfer from original plasmids pS-NLS-
GFP-GST-Jun-NES (02) and pc3-Max-RevM10BL-BFP-gcs (01) delivered by Knauer et al., 2005. 
Additional cloning replaced the GFP by EGFP to increase fluorescence intensity, improve expres-
sion and obtain a more stable red-shifted variant of GFP (protocol #PT2040-1, BD Biosciences 
Clontech). Moreover, the NES sequence was moved upstream of S100A4 since stronger target in-
teractions were expected with a free accessible S100A4 C-terminal. For the bait vector constructs, 
different target sequences; MHC-IIA C-terminal (492 bp) (Kriajevska et al., 1998; Murakami et 
al., 2000; Dulyaninova et al., 2005; Zhang et al., 2005b), p53 C-terminal (177 bp) (Grigorian et 
al., 2001; Chen et al., 2001; Fernandez-Fernandez et al., 2005) and liprin b1 C-terminal (192 bp) 
(Kriajevska et al., 2002) were cloned, replacing the Max sequence (Scheme 1). 
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All the cloned target sequences were holding the putative S100A4 binding site (Fig. 7) that resem-
bled a peptide, obtained from a phage displayed peptide library screening, that was able to inhibit 
S100A4-induced neurite outgrowth (Jörg Klingelhöfer, unpublished data).
 Peptide            H S L R S D W
 p53      G S R A H S S H L K S K K G Q S T
 Liprin b1     G I N N L T H M L K E D D M F K D
 MHC-IIA     A M N R E V S S L K N K L R R G D
 MetAP2     L A F P T G C S L N N C A A H Y T
 Tropomyosin 2    D A E A D V A S L N R R I Q L V E
Putative target sequence for S100A4  S L KS/NK/D
Fig. 7. The putative common S100A4 binding site. Sequences of five S100A4 targets; p53, liprin b1, MHC-IIA, 
methionine aminopeptidase 2 (MetAP2) and tropomyosin 2, aligned together with a peptide sequence obtained by a 
phage displaying library screening. The peptide sequence was able to inhibit S100A4-induced neurite outgrowth. The 
proposed S100A4-interacting region is indicated by the boxed area, constituting the amino acids SLKS/N
K/D.
Based on co-transfections of cloned plasmids and analysis by fluorescent microscopy, it was dis-
covered that the modified translocation system displayed too high background for determining 
specific protein interactions (Jörg Klingelhöfer, unpublished data). Apparently, the empty-target 
BFP protein (RevM10BL-BFP) interacted nearly as good with the shuttle protein (EGFP-GST-
NES-S100A4) in the nucleolis as the fixated BFP protein targets, holding MHC-IIA or p53 respec-
tively (Fig. 8). Also, the first produced GFP-GST-S100A4-NES shuttle was impractical for study-
ing S100A4:target protein interactions due to non-specific interactions (see supplementary I).
This project picks up this problem with the purpose of improving the signal to noise ratio of the 
biosensor so a functional assay will be achieved. 
 % of S100A4 in nucleoli of double fluorescent cells
A4 alone    Control -BFP  MyoCT-BFP    p53CT-BFP
100%
75%
50%
25%
0%
72% 74%
84%
Fig. 8. Co-localization of EGFP-GST-NES-S100A4 and different BFP-fusion proteins. The control BFP-protein 
(RevM10BL-BFP) interacts nearly as good with the shuttle protein EGFP-GST-NES-S100A4 as MHC-IIA (MyoCT-
BFP) and p53-BFP, giving a low signal to noise ratio. 
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Experimental approach for this project
The project approach for establishment of a functional S100A4 biosensor system was commenced 
in two separate ways. 
In the first part, we searched out the S100A4 binding affinities for p53 and MHC-IIA C-terminal 
fragments that were planned to be use in the biosensor system, using Far-Western blotting, ELISA 
and pull-down experiments. Furthermore, we investigated the importance of the putative common 
S100A4 binding interface on p53 and MHC-IIA in vitro, using proteins with introduced site-di-
rected mutations and C-terminal deletions (presented below). 
In the second part, we cloned new shuttle and target vectors to improve the biosensor system and 
reduce the background of nonspecific bindings so S100A4:target-protein interactions could be 
monitored.
RESULTS ON S100A4 BINDING OF p53 AND MHC-IIA IN VITRO
Cloning of S100A4 target proteins
To investigate S100A4 binding affinities for p53 and MHC-IIA in vitro, we first cloned cDNA of 
wild type p53 C-terminal (p53CT, 293-393 aa) and wild type MHC-IIA C-terminal (MHC-CT, 
1878-1961 aa) into the pET151/D-TOPO expression vector (Invitrogen). Additionally, we pro-
duced site-directed mutants of both p53 and MHC-IIA. This was done by quick-change PCR site-
directed mutagenesis, in which the putative common S100A4 interaction site was mutated on p53 
(369-372 aa) and on MHC-IIA (1917-1921 aa). This cloning exchanged Leucine-Lysine-Serine 
(LKS) with Proline-Glycine-Alanine (PGA) on p53 and Serine-Leucine-Lysine (SLK) to Alanine-
Proline-Methionine (APM) on MHC-IIA, as illustrated in figure 9a+b. Moreover, we designed 
PCR primers for PCR cloning and subsequently protein production of p53 C-terminal deletion 
mutants; p53D30 (293-363 aa), p53D37 (293-356 aa) and p53D68 (293-325 aa). Finally, we also 
produced an extreme C-terminal end of the wild type p53 (p53-Ala, 351-393 aa) that was expected 
to bind S100A4 (Fig. 9a) since this fragment included the putative common S100A4 interacting 
site (SLKS/N
K/D). This short fragment could also reveal the importance of the tetramerisation re-
gion on S100A4 binding of p53. 
All the cloned vector constructs were verified by sequencing and all the fusion protein fragments 
were expressed in BL21 bacteria and purified, using affinity chromatography on a FPLC system 
(see material & methods).
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BA
wt-p53 C-terminal   (363-393 aa shown)
GGSRAHSSHL KSKKGQSTSR HKKLMFKTEG PDSD
PGA: p53 mutated from LKS to PGA at 369-371 aa
GGSRAHSSHP GAKKGQSTSR HKKLMFKTEG PDSD
wt-MHC-IIA C-terminal   (1896-1961 aa shown)
LQRELEDATE TADAMNREVS SLKNKLRRGD 
LPFVVPRRMA RKGAGDGSDE EVDGKADGAE AKPAE
APM: MHC-IIA mutated from SLK to APM at 1917-1917 aa
LQRELEDATE TADAMNREVS APMNKLRRGD 
LPFVVPRRMA RKGAGDGSDE EVDGKADGAE AKPAE
293
369-372
393
363
V5V5His TEV
293
V5V5His TEV
consensus
LKSK
consensus
SLKNK
APMNK
1878 1961
1917-1921
V5His TEV
1878 1961
1917-1921
V5His TEV
2-7 8-22 33
293          356
V5His TEV
293
293
325
V5V5His TEV
  PGAK293
369-372
393
V5V5His TEV
369-374
Ala
351 393
V5V5His TEV
p53CT (15.08 kDa)
p53∆30 (11.81 kDa)
p53∆68 (7.23 kDa)
PGA (15.08 kDa)
p53-Ala (8.29 kDa)
MHC-IIA (12.92 kDa)
APM (12.92 kDa)
p53∆37 (10.91 kDa)
326-355
326-355
326-355
326-355
Tetramerisation-region
Fig. 9. Fusion-protein fragments of p53 and MHC-IIA. (A) PCR DNA fragments from wild type p53 and MHC-
IIA C-terminals were cloned directional into the pET151/D-TOPO expression vector (Invitrogen) for protein produc-
tion. The fusion proteins all comprise a polyhistidine region (His), a V5 epitope, a TEV nuclease recognition site, 
followed by different C-terminal protein fragments from p53 and MHC-IIA (notified with the respective amino acid 
residues from the original wild type human proteins). For p53 protein fragments are tetramerisation regions marked 
(amino acid residues 326-355), comprising a b-strand and an a-helix. (B) The putative common S100A4 binding site 
(marked with bold blue) within the wt-p53 (369-372 aa) and wt-MHC-IIA (1917-1921 aa) were subjected to PCR 
site-directed mutagenesis, resulting in a p53 C-terminal PGA mutant and a MHC-IIA APM mutant (mutations marked 
with red bold+underline).
Analysis of the S100A4:p53 binding interface
The S100A4 binding region on the p53 protein has previously been proposed in two reports. 
Grigorian et al. reported the strongest S100A4 binding at the extreme p53 C-terminal (364-393 
aa) due to an expressed p53 C-terminal deletion mutant (p53∆30) had remarkably reduced bind-
ing affinity for S100A4 in pull down experiments (Grigorian et al., 2001). Fernandez-Fernandez 
and colleagues have more recently discovered, by analytical ultra centrifugation analysis of short 
p53 peptides that S100A4 binds stronger to the p53 tetramerisation domain (peptide 325-355 aa). 
However, S100A4 binding was also confirmed to the extreme p53 C-terminal peptide 367-393 aa 
with lower affinity (Fernandez-Fernandez et al., 2005). This could indicate that a larger binding 
interface or more than one binding site exist. 
Our study of S100A4 binding to different p53 mutants will illustrate the importance of which 
amino acid residues that are mainly involved. This will provide useful information of the minimal 
S100A4 binding region needed for S100A4:target-protein interactions in vitro, to support the later 
studies with the biosensor system in vivo. By only using target protein-fragments in BFP-bait con-
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structs, instead of complete proteins, we also expect to diminish cellular protein effects and reduce 
the possible tendency for the BFP biosensor to locate elsewhere than the cell’s nucleolis. 
S100A4:p53 binding studies by Far-Western blotting
To analyse the interface between S100A4 and p53, we were loading wild type p53 C-terminal 
(p53CT) together with the different p53 deletion mutants; p53∆30 and p53∆68 in different con-
centrations (125-500 ng/lane) on a 15% SDS-PAGE. The resulting gel-overlay from Far-Western 
blot (Fig. 10) indicates that both the p53CT and the p53 control fragment (CT control; murine 
p53 289-390 aa) bind S100A4. However, the removal of 30 amino acids of the p53 C-terminal 
(p53∆30) showed the S100A4 binding is strongly reduced just as Grigorian and colleagues report-
ed (Grigorian et al., 2001). Further deletions (p53∆68) completely abolished S100A4 interaction. 
The negative control, displaying the N-terminal part of p53 (p53NT, 1-106 aa) showed no binding 
as well. 
16
6
NT
 co
ntr
ol
CT
 co
ntr
ol
p53CT
500  250  125
p53∆30
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ng:
Fig. 10. S100A4-p53 interactions tested by Far-Western blot. HisV5TEV-p53 fusion proteins were loaded as in-
dicated on top of the blot. As controls, the p53 N-terminal domain (p53NT, 1-106 aa) and the p53 C-terminal domain 
(CT control, murine p53 289-390 aa) were loaded. The lower panel shows the Amido black stained PVDA membrane 
that was incubated with 0.5 µg/ml human S100A4 multimer in the overlay solution. The upper panel shows the 
documented signal detected on X-ray film. The shown result represents an example of 5 replicated experiments. The 
primary anti-S100A4 antibody was used in a dilution of 1:4,000.
Two additional Far-Western blot experiments were performed, in which all p53 protein fragments 
were included to compare S100A4 binding affinities. In addition, all p53 fusion proteins were 
cleaved by AcTEVTM protease to exclude that the HisV5TEV fusion fragment had any influence 
on S100A4 binding. The cleaved proteins were loaded in two concentrations (250 ng/lane and 500 
ng/lane) and analyses by Far-Western blot (Fig. 11). 
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The exchange of the LKS triplet to PGA in the proposed S100A4-p53 target interface lead to a 
remarkably reduced S100A4 binding compared to p53CT (Fig. 11a+b). Additionally, we observe 
no or significantly reduced S100A4 binding affinities for the other p53 mutants in both blots. Pre-
vious blot indicated that p53D68 did not bind S100A4 but appear to bind with low affinity in this 
Far-Western blot (Fig. 11b). This finding might indicate that an extended binding interface exists, 
encompassing the tetramerisation domain (Fernandez-Fernandez et al., 2005). Interestingly, the 
extreme C-terminal p53-Ala fragment, which contains the proposed interaction site, do not inter-
act with S100A4, indicating upstream residues are essential. Finally, the blots show that the 4 kDa 
His-V5-TEV sequence are not implicated in S100A4 binding.
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Fig. 11. Interaction studies between S100A4 and p53 fragments after AcTEV protease cleavage. Lower panels 
A+B shows Amido black staining of PVDA membranes, indicating the positions of the transferred protein fragments. 
The 4 kDa poly-histidine-V5-TEV fragments is weakly visible (see arrows). The upper panels reveal the X-ray film 
developed. (A) 250 ng protein/lane were separated by a 15% SDS-PAGE and transferred to a PVDA membrane. The 
overlay solution contained 0.15 µg/ml human S100A4 multimer. (B) 500 ng protein/lane were loaded. The overlay 
solution contained 0.1 µg/ml human S100A4 multimer. For both blots was used primary anti-S100A4 antibody in a 
dilution of 1:4,000. The two Far-Western blots represent results of two repeated experiments. 
S100A4:p53 interaction studies by pull down assay and ELISA 
To clarify the results obtained by gel overlay, we investigated the interactions between S100A4 
and the different p53 protein fragments by pull-down experiments and ELISA. 
For pull-down experiments we used human recombinant his-tagged S100A4 coupled via primary 
amines to sepharose beads (A4-beads). Since the p53 fusion construct exhibited a V5 epitope, the 
co-precipitated proteins could be detected by a V5 antibody. 
To test the sensitivity of the assay, different concentrations of p53CT (0.1-2.5 µg/ml) were used. 
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Figure 12 illustrates that A4-beads pull down p53CT. The concentration of 0.1 µg/ml was efficient 
to obtain a good signal. Addition of 5 mM EDTA during incubation of the p53CT to A4-beads 
strongly reduced the binding, indicating a calcium dependent interaction.  
      p53CT
       - EDTA           + EDTA
  2.5    0.5     0.1     2.5     0.5
3x
1x
16
µg/ml:
anti-V5
16
Fig. 12. Pull-down of p53CT by S100A4-sepharose beads. In different concentrations (0.1-2.5 µg/ml), p53 C-ter-
minal fusion proteins were incubated together with S100A4-sepharose beads (125 µg/µl). Additionally, 0.5 µg and 
2.5 µg p53 C-terminal were incubated to S100A4-beads in presence of 5 mM EDTA. The two illustrated X-ray films 
from Western blots represent different loadings from the samples after pull-down experiments (volume 3x and 1x). As 
primary antibody we used anti-V5 antibody in a dilution of 1:5,000.
The following pull-down experiments were carried out by separately mixing 50 ng/ml of the 
different p53 fusion proteins to S100A4-sepharose beads (125 µg/µl). The experiments reveal 
stronger co-precipitation of p53CT to A4-beads compared to PGA and p53∆30 mutants (Fig. 13). 
Binding of p53∆37 (293-356 aa) was completely abolished just as we observed it for p53-Ala and 
p53∆68. These data indicate that the last 37 amino acids of p53CT are more important for S100A4 
interaction than residues within the tetramerisation domain.
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Fig. 13. Pull-down of p53 fusion proteins by S100A4-sepharose beads. Lower panels of (A+B) show the Amido 
black stain of PVDA membranes as loading control. The upper panels show Western blots of S100A4 pull-downs. All 
co-precipitations included 50 ng/ml fusion protein mixed with S100A4-sepharose beads (125 µg/µl). Additionally, 
50 ng/ml p53CT was pulled down with uncoupled sepharose beads (Sep). Primary anti-V5 antibody was used in a 
1:5,000 dilution. The results represent examples of three independent experiments.
Finally, we tested interactions between p53CT and S100A4 by ELISA (Enzyme-Linked Immuno-
Sorbent Assay). First, the assay was established by analysing the concentration dependent binding 
of p53CT (0-125 ng/well) to immobilised S100A4 (10 ng/well) on an ELISA 96-well plate. 
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Fig. 14. p53CT affinity to immobilised S100A4 studied by ELISA. S100A4 multimer protein (2 µg/ml) were 
immobilized on an ELISA 96-well plate (greener Microlon) and p53 C-terminal loaded in different concentrations 
(0-125 ng/well) for testing the binding affinity. The data-points represent averages of triplicate measurements and ar-
row-bars showing deviations from averages. For the detection of interactions we used primary anti-V5 antibody in a 
dilution of 1:12,000. The absorbance at 450 nm was measured using an ELISA reader.
We found that the p53CT binding of S100A4 became saturated approximately at 2 ng p53CT/well 
(Fig. 14). Therefore, the following ELISA experiment were performed within the protein concen-
tration range of 0.1-1.6 ng/well.
In the ELISA study of S100A4 binding of p53CT and p53 mutant proteins, we found similar 
S100A4 binding affinities for p53CT and PGA (Fig. 15) in contrast to previous pull-down and Far-
Western blot results. However, the p53∆30 mutant had reduced and p53∆37 significantly reduced 
S100A4 binding affinity just as we discovered by the other in vitro experiments. The ELISA results 
also confirmed a calcium dependent S100A4 interaction of p53CT and PGA mutant, since addition 
of the calcium chelator EDTA (30 mM) throughout the incubation period prevented binding.
Based on at least two in vitro p53 interaction experiments, Far-Western blot and pull-down, the 
S100A4 binding of the PGA mutant was impaired. The p53∆37 could signify the borderline for 
the strongest S100A4 binding interface and this fragment could perhaps show the same tendencies 
in the in vivo biosensor system. p53∆37 or p53∆68 fragments are both candidates for negative 
S100A4-binding controls in BFP-vector constructs and could perhaps be used to validate the spe-
cificity of S100A4:target-protein interactions.
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Fig. 15. Different affinities of p53 fusion proteins toward immobilised S100A4. The wild type p53 C-terminal and 
the different p53-mutants were tested in different concentrations (0.1-1.6 ng/well) for their binding affinities to immo-
bilised S100A4 (2 µg/ml). Calcium dependencies were tested with 30 mM EDTA throughout the ELISA procedure. 
The shown result represents an example of three independent ELISA experiments. Each data-point in both of the il-
lustrated ELISA result pictures represents averages of triplicate measurements. 1:12,000 dilution of primary anti-V5 
antibody was used and absorbance was measured at 450 nm.
Characterization of the S100A4:MHC-IIA interaction site
To find out if the putative common S100A4 binding interface on MHC-IIA might have a similar 
importance as discovered for p53, we tested the binding of the MHC-IIA C-terminal (MHC) and 
the APM mutant to S100A4 by Far-Western blot and pull-down experiments.
Previously, the binding site between the S100A4 dimer and the non-muscle myosin chain A (MHC-
IIA) was mapped to the C-terminal end of the myosin protein (amino acid residues 1909-1937) 
(Kriajevska et al., 1998; Kriajevska et al., 2000; Li et al., 2003; Dulyaninova et al., 2005). This 
part of the protein includes several phosphorylation sites and overlaps with the interface responsi-
ble for the self-assembly of myosin monomers into filaments (Kriajevska et al., 2000; Murakami 
et al., 2000; Dulyaninova et al., 2005). The suggested common S100A4 binding consensus se-
quence (SLKS/N
K/D), described earlier, is also included within the mapped S100A4 binding site 
(SLKNK at 1917-1921 aa). 
First we compared the S100A4 affinity of triplet APM mutant to the wt-MHC by Far-Western blot. 
As shown in figure 16, the APM affinity to S100A4 is reduced compared to MHC. However, un-
like the site-directed mutations we introduced in p53, the change from SLK to APM in MHC-IIA 
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seems to have less effect on the S100A4 binding affinity. Notably, compared to the S100A4-p53 
interaction studies, higher fusion protein concentrations were needed in vitro to detect S100A4-
MHC-IIA interactions. This is in agreement with a previous study by Chen et al., reporting 300-
500 folds higher S100A4 binding affinities of wt-p53 than MHC-IIA C-terminal (149 amino acid 
residues) in vitro (Chen et al., 2001). 
16
         1x               2x
MHC   APM   MHC   APM
anti-S100A4
Fig. 16. S100A4 interactions between MHC and APM tested by Far-Western blot. MHC-IIA and APM proteins 
were loaded in single and double concentrations (0.25 and 0.5 µg/well). Note that myosin fragments aggregates, so 
the visualised monomer protein concentrations on the Amido black stain PVDA membrane (lower panel) are approxi-
mated. We used overlay solution with human S100A4 multimer in a 0.2 µg/ml concentration. The upper panel shows 
the signal detection by Western blot (repeated 3 times), using primary anti-S100A4 antibody in dilution 1:4,000. 
To verify the results above, we performed pull-down experiments as well (Fig. 17). By this method 
we showed that MHC binds S100A4-sepharose beads and the APM mutant has impaired binding 
affinity. Additionally, the EDTA control (5 mM) showed calcium dependent binding and further-
more, no binding of MHC was observed to sepharose beads alone (Sep.).
                     S100A4-beads                 
  Sep.      - EDTA       + EDTA     Sup.
MHC  MHC  APM MHC APM MHC  APM
anti-V5
16
Fig. 17. Pull-down of MHC and APM by S100A4-sepharose beads. Equally amount of MHC and APM fusion pro-
teins (2.5 µg/ml) were incubated with S100A4-sepharose beads (125 µg/µl) in absence or presence of 5 mM EDTA. 
Supernatant controls (Sup) were taken before pull-down and loaded as protein concentration controls. (A) Amido 
black staining of the PVDA membrane, used as loading control and shows S100A4 protein from sepharose beads. (B) 
Shows the developed X-ray film from Western blot. The experiment was repeated 3 times with the same result. For 
primary antibody was used anti-V5 in a 1:5,000 dilution.
Based on the presented in vitro results, the putative common S100A4 interface on p53 and MHC is 
involved in S100A4 interactions. The S100A4 bindings are calcium sensitive, indicating specific 
target affinities. Furthermore, the C-terminal fragments of p53 and MHC-IIA seem to be sufficient 
for observing S100A4:target complexes in vivo. 
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First, the biosensor system was re-modified by new cloning engineering of prey and bait vectors. 
Secondly, the new vectors were tested by single and co-transfections of Cos-7 cells to monitor 
possible improvement of the biosensor, regarding specific interactions and signal to noise ratios. 
Cloning engineering of AcGFP and BFP biosensor constructs
The fluorescence proteins GFP and BFP can form heterodimers when expressed together in cells 
at high concentrations (review Stauber et al., 1998) just as EGFP (Chen et al., 2003). This effect 
could be a reason for low signal to noise ratios and prevent interactions between target and shuttle 
proteins. Consequently, to reduce false positive interactions, we encoded cDNA of a green fluores-
cence protein true monomer (AcGFP) (BD Biosciences, Clontech) by directed PCR cloning. This 
replaced the EGFP from the shuttle vector by AcGFP, as illustrated in Scheme 2. 
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Scheme 2. New biosensor vectors constructed by PCR clonings. The start point for BFP-vector clonings was from 
the original plasmid pc3-Max-RevM10BL-BFP-gcs (01), delivered by Knauer et al., 2005. For AcGFP-vectors clon-
ings, pS-NLS-EGFP-GST-NES-S100A4-NES (44), provided by Jörg Klingelhöfer, was used as plasmid template. All 
cloned vectors were sequenced for verification of successful cloning. 
By conducting a NES/GST cloning, we moved the NES to observe any possible difference in 
steady-state shuttle localization and deleted the GST sequence to avoid any possible binding non-
specificities, originating from this fusion part. For further optimization, we also cloned new BFP 
bait-vectors as well. Here we moved cDNA sequences of the protein targets (liprin b1, MHC-IIA 
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and p53) to the C-terminal of the vector constructs. This was expected to optimize S100A4 bind-
ings since free accessible target C-terminals resemble more the in vivo interaction sites. 
Sub-cellular localization of shuttle proteins in Cos-7 cells
First, we tested the shuttle protein ability to fluctuate between the nucleus and the cytoplasm. The 
original NLS-GFP-GST-S100A4-NES fusion protein was found preferentially in the cytoplasm in 
Cos-7 (Fig. 18a) just as we observed it in other cell lines; Hela, HEK, VMR and MCF-7 cells (data 
not shown). After adding leptomycin B, an inhibitor of nuclear export (Wolff et al., 1997; Kudo et 
al., 1998) the fusion protein accumulated in the nucleus compartments of Cos-7 cells (Fig. 18b), 
indicating that the protein shuttles between the nucleus and the cytoplasm. 
GFP S100A4
NESNLS
GFP GFP
control Leptomycin
t = 1 hour
A                B
Fig. 18. Shuttle ability of the GFP-GST-S100A4-NES protein in Cos-7 cells. (A) The steady-state localization of 
the NLS-GFP-GST-S100A4-NES (03) is normally monitored predominately the cytoplasm by fluorescence micros-
copy. (B) Nuclear accumulation of the shuttle protein was observed 1 hour after adding leptomycin B to Cos-7 cells 
in the green filter channel (Jörg Klingelhöfer, unpubl. data).
Fusion proteins, where the NES was moved from the extreme C-terminus of the shuttle protein 
in front of S100A4 (EGFP-GST-NES-S100A4 or AcGFP-GST-NES-S100A4), showed a stronger 
nuclear steady-state accumulation compared with the original shuttle protein (Fig. 19). 
It has been reported that masking the NES sequence could cause nuclear accumulation due to 
decreased nuclear export (Gama-Carvalho & Carmo-Fonseca 2001). The upstream NES could 
to some extend be hidden by surrounding amino acids in the fusion shuttle protein, resulting in 
less nuclear export. These shuttle protein constructs make interpretation of co-localization to the 
nucleus/nucleoli more difficult, due to preferential nuclear localization.
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S100A4GFP S100A4EGFP AcGFP S100A4
Fig. 19. Expression of different GFP-shuttle-S100A4 vectors in Cos-7 cells. The shown pictures includes: GFP-
GST-S100A4-NES, EGFP-GST-NES-S100A4 and AcGFP-GST-NES-S100A4. The illustrated pictures were all taken 
of fixated Cos-7 cells on coverslips, expressing green fluorescence shuttle-S100A4 vectors and monitored by fluores-
cence microscopy at 40x zoom in the green filter channel.
Unexpected, the GST-free AcGFP-S100A4-NES shuttle showed also stronger nuclear distribution 
(Fig. 20) than the original GFP-GST-S100A4-NES. The lack of GST or the shorter size of protein 
might be the reason for the nuclear accumulation.
AcGFP S100A4
Fig. 20. AcGFP-S100A4-NES expressed in Cos-7 cells. The illustrated picture was taken by fluorescence micros-
copy at 40x zoom in the green filter channel of fixated cells on coverslips.
Taking together, the original GFP-GST-S100A4-NES protein has better sub-cellular cytoplasmic 
localization but, as previously mentioned, GFP can dimerise with BFP (review Stauber et al., 
1998). This was supported by co-transfections of pS-NLS-GFP-GST-NES and pN-RevM10BL-
BFP that revealed co-localizations in nucleolis, which also was monitored between the GFP-GST-
S100A4-NES and RevM10BL-BFP proteins (see supplementary I). 
The AcGFP shuttles should avoid this dimerisation problem and by using the AcGFP-GST-NES-
Results 
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S100A4 shuttle, we might obtain an advantage in target binding due to a free accessible S100A4 
C-terminal. However, this type of shuttle construct accumulates mainly in nucleus (as shown 
above) but importantly the nucleolis are general free of GFP signal, in which co-localizations can 
be observed. 
To clarify, which of the two AcGFP shuttle proteins are most useful as biosensors, we tested the 
cellular co-localization of each fusion protein together with the BFP fusion control protein.
Testing the biosensor translocation system
The pN-RevM10BL-BFP control, carrying no target sequence, was co-transfected with the pS-
AcGFP-S100A4-NES and the pS-AcGFP-GST-NES-S100A4 respectively. After 24 hours, the ex-
pressed proteins in Cos-7 cells were monitored by fluorescence microscopy. 
We found significant co-accumulations between the AcGFP-GST-NES-S100A4 and the RevM-
10BL-BFP protein in the nucleolis (Fig. 21), which were GFP-free in single AcGFP shuttle trans-
fections. We observe similar co-localizations between the AcGFP-S100A4-NES and RevM10BL-
BFP proteins in the nucleolis, though these were not free of AcGFP signal in single transfections. 
AcGFP S100A4
BFPNA
BFPNA
AcGFP S100A4
GFP Merge BFP
GFP Merge BFP
Fig. 21. Co-transfection controls between AcGFP shuttles and RevM10BL-BFP. Fluorescence microscopy pic-
tures from co-transfections of pN-RevM10BL-BFP+AcGFPGST-NES-S100A4 and pN-RevM10BL-BFP+AcGFP-
S100A4-NES. Cos-7 cells are magnified 40x and the picture from the green and the blue channel was taken independ-
ently and then merged (blue color was exchanged to red color for better visualisation of co-localization, indicated as 
yellow/orange).
The change of the GFP with the true monomer fluorescence protein AcGFP did not prevent the 
high nonspecific binding problems as encountered before by Jörg Klingelhöfer. Co-localization of 
AcGFP shuttle proteins in combination with different target BFP proteins could therefore not be 
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considered as specific interactions, since co-accumulation in nucleolis occurred independently of 
target sequences present (e.g. supplementary I). 
The new C-terminal BFP target plasmids and BFP control plasmid showed unfortunately to poor 
transfection efficiency to Cos-7 cells, which made the plasmids not suitable for co-transfection 
experiments. In order to address this problem, we tested for cell apoptosis that could be induced 
by the expressed vectors. Our results indicate that the level of apoptotic cells were not significant 
different compared to the N-terminal target BFP vectors, suggesting other reasons for low protein 
expressions, maybe due to low DNA quality (described in supplementary II).
In search for answering the biosensor problem, the original vectors acquired from Knauer and her 
team were first examined for possible different sub-cellular protein localization in our cell lines. 
Originally the Max-RevM10BL-BFP and GFP-GST-Jun-NES protein constructs do not interact in 
Hela cells (Knauer et al., 2005). This we verify in both Cos-7 (Fig. 22a), MCF-7 and Hela cells 
(data not shown). Testing for possible interaction between RevM10BL-BFP and GFP-GST-Jun-
NES did not result in nonspecific binding either (Fig. 22b). Based on these results, the transloca-
tion biosensor system therefore basically works in our cell lines.
BFPNAMax
GFP Jun
BFPNAMax
GFP Jun
BFPNA
GFP Jun
GFP
GFP
Merge
GFP Merge
BFP
BFP
BFP
Fig. 22. Original vector constructs expressed in Cos-7 cells. Pictures of GFPGST-Jun-NES + Max-RevM10BL-
BFP, GFPGST-Jun-NES + RevM10BL-BFP and single expressions of the two vectors. The fixated Cos-7 cells on 
coverslips were magnified 40x and the picture from the green and blue channel was then merged (blue color was 
exchanged to red color for better visualisation of possible co-localization, indicated as yellow/orange).
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To test the biosensor system further, we investigated the reason for the observed nonspecific bind-
ings of S100A4 shuttle vectors by pull-down experiments of protein cell extracts. 
From Cos-7 cells, either expressing RevM10BL-BFP (14), p53-BFP (04), GFP-GST-S100A4-
NES (03) or AcGFP-S100A4-NES (86) fusion proteins, cell extracts were made. The protein cell 
extracts were incubated with either S100A4-sepharose (A4-beads) or Glutathione-sepharose 4B 
beads (GSH-beads) and pulled down to investigate the origin of nonspecific interactions between 
RevM10BL-BFP and S100A4-shuttle constructs. Co-pretipitated proteins were analysed by West-
ern blotting. 
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Fig. 23. Pull-down of different protein extracts by S100A4 or GSH-sepharose beads. (A) Illustrates the de-
veloped X-ray films from Western blot after precipitation and co-precipitation of GFP-GST-S100A4-NES (03) and 
RevM10BL-BFP (14) by S100A4-sepharose (A4-beads) or Glutathione-sepharose 4B beads (GSH-beads) or sepha-
rose beads (Sep.). (B) Western blot after pull-down of AcGFP-S100A4-NES (86) and p53-RevM10BL-BFP (04) by 
A4-beads. Supernatant controls were taken before pull-down and separated as controls by SDS-PAGE (8% gel). For 
the Western blots were used primary anti-GFP antibody in a dilution of 1:2,000.
As shown in figure 23a, A4-beads pulled down the RevM10BL-BFP protein, in contrast to GSH-
beads, indicating only binding between the RevM10BL-BFP protein and S100A4 takes place. 
However, a protein mixture of GFP-GST-S100A4-NES+RevM10BL-BFP did not co-precipitate 
RevM10BL-BFP by GSH-beads (pull-down GST) though, GSH-beads might prevent RevM10BL-
BFP binding of the shuttle protein simultaneously. Control experiments additionally revealed 
interactions between A4-beads and p53-RevM10BL-BFP or AcGFP-S100A4-NES respectively 
(Fig. 23b), while the RevM10BL-BFP did not bind sepharose beads alone (Fig. 23a). 
Additional pull-down analyses, using AcGFP-GST-NES-S100A4 (85), GFP-GST-NES (15) and 
RevM10BL-BFP, supported these observations and showed that RevM10BL-BFP interacts pref-
erentially with S100A4 and not with the GST sequence (data not shown). 
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Finally, to test if the observed S100A4 affinities included the BFP or the RevM10BL protein frag-
ment of the bait vector, we used a RevM10BL-mRFP (red fluorescence protein) control. 
Co-expressions of pN-RevM10BL-mRFP (provided by Jörg Klingelhöfer) and the pS-AcGFP-
S100A4-NES vectors in Cos-7 cells showed once more co-accumulation in nucleolis (Fig. 24), 
suggesting the RevM10BL sequence is the cause of nonspecific interactions to S100A4. Addition-
ally, we only observe weak co-localization of RevM10BL-mRFP and the S100A4-free shuttle 
GFP-GST-NES. However, the interpretation of this result was more difficult since the RevM-
10BL-mRFP did not accumulate as strong to the nucleoli as the RevM10BL-BFP, giving overlap-
ping fluorescence signals from the same sub-cellular localisations.
NA BFPNA mRFP1
NA
GFP
mRFP
NA mRFP
AcGFP S100A4
RFP
GFP Merge RFP
GFP Merge RFP
Fig. 24. Single and co-expressions of pN-RevM10BL-RFP control in Cos-7 cells. Fluorescence microscopy pic-
tures of RevM10BL-RFP+AcGFP-S100A4-NES and RevM10BL-RFP+GFP-GST-NES. In lower panel, single ex-
pression of RevM10BL-RFP and RevM10BL-BFP are monitored respectively. The fixated Cos-7 cells on coverslips 
were magnified 20x and 40x and pictures taken separately from green and red channels and merged afterwards.
Summarized, the shown data supports that S100A4 interacts with a part of the BFP fusion pro-
tein, most probably with the RevM10BL sequence, which is needed for nucleolar localization. 
This unwanted interaction excludes studying S100A4 in vivo protein-protein interactions by this 
translocation system, since the S100A4-shuttle and RevM10BL-BFP co-localize in the nucleolis 
independently of target sequences. 
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DISCUSSION
The protein translocation biosensor system
The previous established S100A4 biosensor translocation system (constructed by Jörg Klin-
gelhöfer) displayed significant nonspecific interactions. Because BFP:GFP could dimerise, we 
searched out other possible shuttle and bait biosensors that possibly could have more specific 
binding affinity. 
The performed shuttle vector modification (AcGFP cloning) did however not decrease the nucleoli 
co-localizations between the AcGFP-GST-NES-S100A4 shuttle and the nucleoli fixated RevM-
10BL-BFP control. Moreover, we monitored that they interact due to the nucleolis normally were 
free of AcGFP signal in single expressions of AcGFP-GST-NES-S100A4. BFP:GFP dimerisation 
was therefore not the reason for the observed nonspecific binding. 
From pull-down experiments, it became clear that RevM10BL-BFP had binding affinity to S100A4 
while the GST sequence caused no unwanted interactions. Because the RevM10BL-BFP is part of 
the target fusion proteins, we cannot distinguish if the monitored S100A4-shuttle and BFP-target 
interactions are specific or not. It was expected, for the S100A4 target binding interface that in-
teractions would occur mainly through complementation of hydrophobic amino acid residues and 
+/- charges (review Donato 1999). Within the RevM10BL-BFP both partial positive, negative and 
hydrophobic regions are present, which theoretically could constitute some residues with S100A4 
binding affinity. 
From co-transfections of Cos-7 cells with pS-AcGFP-S100A4-NES and pN-RevM10BL-mRFP, 
we found the RevM10BL sequence is more likely to be the reason for S100A4 interaction than 
BFP. Based on the obtained results, we therefore suggest that the translocation biosensor needs to 
be revised by further experimental cloning replacing the RevM10BL with another NES deficient/
nucleoli fixating fragment, for instance the sequence from the nucleolar dyskerin protein (Heiss 
et al., 1999). This may be sufficient for achieving a functional S100A4 biosensor system with 
increased binding specificity. 
Furthermore, our results reveal that the design of shuttle vectors, in respect of the NES location, is 
important. We found that the NES sequence should be located at the C-terminal for proper protein 
nuclear export, which was clearly revealed by comparing sub-cellular localization of the shuttle 
proteins NLS-GFP-GST-S100A4-NES and NLS-AcGFP-GST-NES-S100A4. By performing the 
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NES/GST cloning, we obtained a shuttle GST-free fusion protein, AcGFP-S100A4-NES, which 
also showed changed shuttle ability. This fusion protein showed preferentially nuclear steady-state 
localization, implying that there might be a structural importance for the shuttle capability given 
that the GST-free shuttle AcGFP-S100A4-NES appears to reduce the nuclear protein export. The 
nuclear retention could be associated by stronger affinity of certain nuclear proteins, although the 
problem is difficult to address due to the complexity of the nuclear transport system and possible 
cellular modulations taking place (reviews by Ossareh-Nazari et al., 2001; Bednenko et al., 2003; 
Gasiorowski & Dean 2003). 
In the original description of the translocation biosensor system, Knauer and colleagues illustrates 
a preferential cytoplasmic localization in all shuttle derivatives of NLS-GFP-GST-“prey”-NES, 
with prey in sizes of 80-118 aa, though they do not describe shuttles without GST (Knauer et al., 
2005). The GST, or the fusion construct size and the way the sequences are linked, seems to be 
essential for the export of the shuttle fusion proteins since we only observe the NLS-GFP-GST-
S100A4-NES preferentially in the cytoplasm (size of S100A4 101 aa; review Barraclough 1998).
Beside the mentioned problems above, the S100A4-biosensor should not influence the proper ac-
tive binding structure of S100A4. The S100A4 intracellular target binding takes normally place 
as a calcium bound dimer. The S100A4 structural arrangement and the ability to complement 
charges and hydrophobic residues on targets are essential for specific binding, mostly occurring in 
a calcium dependent manner (Zhang et al., 2005b). In fusion with a fluorescence marker, S100A4 
could have impaired structural folding and reduced calcium binding affinity. In that case, studies 
of the cellular monomer S100A4 protein:protein interactions will not work. On the contrary, our 
pull-down experiment of p53-RevM10BL-BFP and AcGFP-S100A4-NES by S100A4-sepharose 
beads indicates that interactions are possible. Moreover, Zhang and colleagues reported that an 
enhanced cyan fluorescence protein fused to S100A4 (ECFP-S100A4) interacts in vivo with the 
MHC-IIA-EYFP fusion protein (comprising a fusion between the 149 aa MHC-IIA C-terminus 
and enhanced yellow fluorescence protein). Interactions were observed by fluorescence resonance 
energy transfer (FRET) and by fluorescence lifetime imaging microscopy (FLIM) (Zhang et al., 
2004) and suggest that S100A4 fusion constructs can interact with N-terminal fusion targets. The 
group also showed, by the same method, that ECFP-S100A4 and S100A1-EYFP dimerisation 
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takes place in vivo. They also showed that S100A1 interaction reduced S100A4 inhibition of 
MHC-IIA filament formation and phosphorylation in vitro (Wang et al., 2005). Hereby, it seems 
plausible that the translocation biosensor system in principle could work for S100A4. 
To study S100A4:target co-localization in cells nucleolis, the biosensor system could be modified in 
an reverse order. First of all, this would provide a free accessible C-terminal end of S100A4 (BFP-
RevM10BL-S100A4) and secondly, this might abolish or reduce the nonspecific interactions with 
BFP-RevM10BL. Third, the cloning of NLS-AcGFP-GST-“S100A4-targets”-NES might provide 
better sub-cellular steady-state localization in the cytoplasm, compared to the produced AcGFP-
S100A4 shuttles. Additionally, after obtaining this biosensor system it would be advisable to per-
form in vitro experiments to study the effects of calcium dependency and dimer/oligomerisation 
between S100A4:S100A4 and target:target, in order to fully describe the system. This is important 
since many S100A4 targets; MHC-IIA, liprin 1b and p53 can dimerise or oligomerise (Li et al., 
2003; Kriajevska et al., 2002; Kitayner et al., 2006). Plausibly, this would reduce S100A4:protein 
target interactions because of the oligomerisation domains are located close or within the known 
S100A4 binding sites (Murakami et al., 2000; Fernandez-Fernandez et al., 2005; Dulyaninova et 
al., 2005). Further, the biosensor translocation system could be improved by using inducible ex-
pression biosensor vectors, to obtain a control of protein expression levels (Knauer et al., 2005). 
Adding a more flexible linker between BFP/GFP markers and the interacting proteins of interest 
might also accommodate better protein-protein associations in the assay (Hu & Kerppola 2003). 
Other protein-protein interaction studies could also be undertaken. Previously, the two-hybrid 
yeast system was tested in our laboratory for different S100A4 protein targets. However, this 
investigation only resulted in observation of S100A4 dimers and S100A4-S100A1 complexes 
(Tarabykina et al., 2000). Therefore, achieving a functional S100A4:target-protein interacting as-
say in vivo, is still a challenge. 
Common S100A4 binding interface on p53 and MHC-IIA
Considering the obtained in vitro results, we found strong evidence that the proposed S100A4 tar-
get site (SLKN/S
K/D) is involved in the calcium dependent S100A4 binding of MHC-IIA and p53. 
The common consensus sequence is comprised of hydrophobic, polar and charged amino acid 
residues. At least some of these are likely important residues that complement electrostatic forces, 
Discussion 
Master Thesis by Henrik Devitt Møller
39
hydrophobic and/or polar interactions with the S100A4 binding interface. 
The site-directed mutations in p53 (LKS to PGA) and in MHC-IIA (SLK to APM) introduced non-
polar hydrophobic residues. In both mutants, serine, leucine and lysine residues were removed and 
we show in pull-down experiments that these mutants have reduced S100A4 binding affinities. 
This imply that these residues could be key attachment points for S100A4 and a combination of 
binding forces may be restricting S100A4:target-binding. 
Our idea that various S100A4 intracellular target proteins have resembling binding sites, seems 
therefore plausible. Interestingly, our predicted S100A4-interacting sequence is often found di-
rectly or in close proximity of homo-dimeric interfaces of different targets. Moreover, they often 
contain phosphorylation and acetylation sites as well, suggesting a general role of S100A4 on 
regulation of protein assemblies and protein phosphorylation/acetylations. 
However, based on our other in vitro studies, the putative S100A4 binding site might not be suf-
ficient to knockdown S100A4 binding since we found similar S100A4 binding of wt-p53 and 
PGA in ELISA studies, just as we observed it for MHC-IIA and APM in Far-Western blots. Addi-
tional site-directed mutations of the remaining residues in the proposed interaction site of p53 and 
MHC-IIA would probably abolish the observation of S100A4-binding completely in pull-down 
experiments and show observable effects in ELISA and Far-Western blot studies. These additional 
studies are needed to support the obtained results from pull-down experiments and clarify, if the 
abolishment of the consensus site is enough to prevent binding. If this is proven, a small molecu-
lar drug might be able to inhibit several S100A4 functions through blocking of its interactions to 
several intracellular proteins (e.g. liprin b1, p53, MHC-IIA). On the other side, if S100A4 binding 
cannot be depleted by additional site-directed mutations, it could indicate that additional redun-
dant binding sites are involved.
The possible existence of a common binding site has been tested for another S100 member, the 
S100B protein. S100B also has multiple protein targets and studies revealed a consensus motif 
is present within several potential targets (McClintock & Shaw 2000). An inhibitory peptide se-
quence for S100A1 and S100B is also reported for several of their protein targets (Ivanenkov et 
al., 1995; Garbuglia et al., 1999; McClintock et al., 2002; McClintock & Shaw 2003). In addition, 
small molecule inhibitors (e.g. pentamidine) could inhibit S100B binding of p53 (Markowitz et 
al., 2004+2005). Based upon this evidence and our reported data, a common binding motif on 
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intracellular S100A4 protein targets is likely to exist. 
Already, peptide nucleic acids have been used to down regulate S100A4 protein levels more than 
90% in cell lines, all containing inducible S100A4 gene model systems. The cellular uptake of 
peptides was independent of an additional transfection reagent (Bøe & Hovig 2006), providing a 
simple way to down regulate S100A4. Directed peptides against S100A4 or S100A4 targets could 
therefore be a therapeutic approach for controlling key initiating events in the metastatic process, 
which also is proposed in the literature (Xue et al., 2003). 
Possible function of S100A4 through MHC-IIA binding
MHC-IIA has two known phosphorylation sites in the C-terminal domain; serine 1917 and serine 
1944, phosphorylated by protein kinase C (PKC) and casein kinase 2 (CK2) respectively. We 
show, S100A4 binding of MHC-IIA includes the proposed consensus sequence on SLKNK (1917-
1921 aa) that covers the Ser1917 phosphorylation site and very well could be important in S100A4 
regulation of MHC-IIA functions. 
Kriajevska and colleagues have obtained data on this and reports that both phosphorylation sites 
are inhibited in the S100A4-MHC-IIA bound state in vitro (Kriajevska et al., 1998). Strangely, 
the phosphorylated Ser1917 within the S100A4 consensus sequence still enables S100A4 binding 
(Dulyaninova et al., 2005), indicating that Ser1917 phosphorylation possibly regulates another func-
tion. The phosphorylated CK2 site however decreases S100A4 affinity for MHC-IIA approximate-
ly 6.5 folds, indicating a mechanism to protect MHC-IIA against S100A4 induced disassembly 
(Dulyaninova et al., 2005). 
Several papers have shown that S100A4 binds preferentially to the non-muscle myosin heavy 
chain isoform IIA and not appreciably to the homologous isoform MHC-IIB (Murakami et al., 
2000; Li et al., 2003; Dulyaninova et al., 2005), even though in most cell types of higher ver-
tebrates they are equally present. Comparing the MHC-II isoforms, showed electrostatic charge 
differences of the amino acids in the C-terminal tail domain (Fig. 25) (Dulyaninova et al., 2005). 
Discussion 
Master Thesis by Henrik Devitt Møller
41
extended ACD
S100A4
Fig. 25. The non-muscle myosin heavy chain isoform A and B. The structure above shows the MHC-IIA a-helical 
coil and below the MHC-IIB a-helical coil. S100A4 binds preferentially MHC-IIA in the extreme C-terminal end 
within the MHC-II assembly competence domain (ACD) and the amino acid residues 1909-1924. Blue and red colors 
represent the positive and negative electrostatic potential of the amino acid residues 1730-1928 and yellow marks the 
serine 1917 PKC phosphorylation site. Modified after Dulyaninova et al., 2005.
It seems likely that S100A4 could be repelled more by the positive amino acid charge region on 
MHC-IIB, compared to MHC-IIA, and the close proximity of +/- charges on MHC-IIA might be 
recognized by S100A4.
Generally, MHC-IIA+B are reported to influence various cell activities such as; cytokinesis, cell 
adhesion, secretion, division, membrane trafficking and cell motility (Kriajevska et al., 1998; re-
views by Tarabykina et al., 2007). MHC-IIA and B have also been shown to distribute in isoform 
specific patterns within moving cells (reviews by Kriajevska et al., 2000; Murakami et al., 2000; 
Tarabykina et al., 2007). The mechanism for S100A4 modulation of MHC-IIA could therefore be 
a way to manipulate only one of the isoforms due to slightly different properties. 
Disassembly of the MHC-IIB isoforms have been shown to be promoted by phosphate groups 
introduced by either PKC or CK2 (review Murakami et al., 2000). The introduction of the partial 
negative charge of the phosphate group is a plausible reason for preventing myosin filament as-
sembly (Dulyaninova et al., 2005), however phosphorylation of MHC-IIA seems not to have the 
same disassembly impact as discovered for MHC-IIB (review Murakami et al., 2000). 
Instead, it is speculated that MHC-IIA disassembly is facilitated by the S100A4 protein (review 
Tarabykina et al., 2007) and perhaps works through a similar charge repulsion strategy as the 
phosphate group. The phosphorylation of Ser1917 on MHC-IIA could therefore instead be associ-
ated with inhibition of the overall accumulation of MHC-IIA and MHC-IIB heterodimers (Mu-
rakami et al., 2000; Dulyaninova et al., 2005).
Summarized, homologous filaments could be favourised by MHC-IIA phosphorylations and 
through separate mechanisms filaments could be regulated; S100A4 acting on MHC-IIA and 
Discussion 
42
Establisment of a Translocation Biosensor to monitor S100A4:Target Protein Interactions in living cells
phosphate groups on MHC-IIB. 
In theory, S100A4 could facilitates MHC-IIA disassembly for quick turn-over in one end of fila-
ments with assembly occurring simultaneously in the other end. Beside migrating cells, many 
other MHC-IIA functions could be affected by S100A4, though more research is needed to clarify 
such influences.
The S100A4 possible influence through p53-binding
The S100A4 influence on p53, having multiple functions, cover naturally several areas in the cel-
lular system. Additionally, beside the S100A4 protein, p53 is also influenced by the S100B mem-
ber that also binds wt-p53 at the C-terminal end. This could suggest a complex p53 regulation by 
S100A4 and S100B, which we investigated briefly.
S100A4 & S100B both bind and regulate p53
From the literature, the Ca2+-dependent S100B binding of p53 is reported within the same region 
as the S100A4 binding domain and could have similar functions as S100A4 (Baudier et al., 1992; 
Rustandi et al., 1998+1999; Delphin et al., 1999; Scotto et al., 1999; Lin et al., 2004; Markowitz 
et al., 2004; Fernandez-Fernandez et al., 2005; Wilder et al., 2006). Theoretically, p53 could pro-
vide binding of S100A4 and S100B simultaneously, which could have synergistic roles on p53 
regulation. 
Based on competitive p53 binding experiments, using ELISA, we found that the binding of p53 by 
S100A4 and S100B was competitive, which suggests a overlapping binding site (see supplemen-
tary III). Therefore it is unlikely that there is any coordinated regulation of p53 between S100A4 
and S100B. Their possible related roles on p53 regulation, could simply be dictated by the cellular 
tissue, since many cell types only have one of the proteins expressed, e.g. S100B is only found in 
the brain (reviews by Zimmer et al., 1995; Donato 1999; Yao et al., 2007). Moreover, the nucleus 
associated S100A2 protein also binds p53, which could indicate additional p53 regulation adjusted 
to the sub-cellular cell compartments (Mueller et al., 2005). 
S100A4 modulates p53 oligomerisation & phosphorylation/acetylation
For p53-dependent transcription, it is known that the active p53-DNA binding form is comprised 
of a pair of p53 dimers (Fig. 26) (Clore et al., 1995; review May & May 1999; Kitayner et al., 
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2006; Wilder et al., 2006). Formation of S100A4/B-p53 complexes favourites the p53 monomer, 
while the p53 tetramer makes both S100A4 and S100B bind less efficiently (Baudier et al., 1992; 
Fernandez-Fernandez et al., 2005; Kitayner et al., 2006). The S100A4 binding near the p53 C-ter-
minal oligomerisation domain (TET) is likely a reason for p53-tetramer destabilization. Further-
more strong S100A4 binding to the TET-region is reported in low p53 concentrations (Fernandez-
Fernandez et al., 2005) underlining an S100A4 regulatory effect on p53 oligomerisation.
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Fig. 26. Model of the p53 tetramer bound to DNA. The p53 tetrameric complex at left illustrates a core tetramer 
(each p53 monomer different color), unstructured chains (dotted lines) connecting to the C-terminal tetramer (shown 
as connected rectangles) and the extreme C-terminal domains (CTDs), shown as curved arrows. The right figure illus-
trates the partially open complex dissociated into two p53 dimers. The open pair of p53 dimers could be destabilised 
by S100A4 through binding near the tetramerisation domain. Modified after Kitayner et al., 2006.
Our results verify that S100A4 binding requires the p53 TET-region. We discovered that the wt-
p53-Ala protein fragment (351-393 aa) did not bind S100A4, despite the fact that the fragment 
contains the S100A4 interaction site. From the secondary structure of the p53 C-terminal (Fig. 
27), the amino acid residues upstream of the wt-p53-Ala peptide comprises the TET domain, con-
sisting of a b-strand and an a-helix structure (325-356 aa). This structural protein feature seems 
to provide necessary binding stability for S100A4-p53 interaction, since removing this region 
abolished S100A4 binding to p53. Moreover, we identified weak S100A4 binding of the p53D68 
(293-325 aa) by Far-Western blotting ,which might indicate that an extending binding interface 
exists, encompassing the tetramerisation domain. However, the high excess of p53D68 protein 
(500 ng/lane) could respond to retained S100A4 in the experiment and not actual binding. On 
the other hand, p53 peptides (305-322 aa) were shown in a previous study to bind S100A4 with 
low affinity (Fernandez-Fernandez et al., 2005). Our reported in vitro results from ELISA and the 
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pull-down experiments, did not take oligomerisation of fusion proteins into account, which could 
undermine actual S100A4 interactions of p53D37 in low oligomeric states that could support TET-
binding more clearly. 
Summarized, the binding interface between S100A4 and p53 seems to cover a large C-terminal 
area on p53, destabilising the tetramer and favouring the monomer form, just as reported for 
S100B (Baudier et al., 1992; Fernandez-Fernandez et al., 2005; Kitayner et al., 2006).
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Fig. 27. Model of the p53 C-terminal structure. The human wild type p53 C-terminal of the amino acids 305-393 
with its known secondary structure and the putative common S100A4 binding site marked (amino acids 369-373). 
The oligomerisation domain (TET-region) is comprised of a turn (Asp324-Gly325), a b-strand (Glu326-Arg333), a second 
turn (Gly334), an alpha-helix (Arg335-Gly356), in which two monomers can form anti-parallel a-helices and b-strands. 
Nuclear localization signal 1 (NLS-1) 305-322 is the most active in nuclear import and the most conserved. Also illus-
trated is the PKC (Ser371, 376, 378) and CK2 (Ser392) phosphylations sites, marked in green and acetylation sites (Lys372, 373, 
381, 382) marked in blue. As well: NLS-II 370-376 (LKSKKGQ), NLS-III 380-386 (RHKKLM) and the nuclear export 
signal (NES) 340-351 with the oligomerisation region. Modified after Shaulsky et al., 1990; Clore et al., 1995; Tao & 
Levine 1999; Chene 2001; Liang & Clarke 2001; Fernandez-Fernandez et al., 2005.
As illustrated in figure 27, several phosphorylation and acetylation sites exist near the putative 
common S100A4 site. These includes phosphorylation sites at serines 371, 376, 378 and 392 
and acetylations sites at lysines 372, 373, 381 and 382 (Ahn & Prives 2001; Friedler et al., 2005; 
Wilder et al., 2006). From the literature, occupation of these sites seems to influence p53 oligom-
erisation and transcription activation. Previously, p53-S100A4 and p53-S100B complexes was 
shown to inhibit p53 C-terminal PKC phosphorylation and acetylation. Moreover, S100B affini-
ties for p53 deceased if some sites were occupied (Baudier et al., 1992; Delphin et al., 1997+1999; 
Scotto et al., 1999; Markowitz et al., 2004; Wilder et al., 2006; reviews by Liang & Clarke 2001; 
Helfman et al., 2005). The role of S100A4 and phosphorylation on p53 could be counterparts to 
each other, just as discussed for MHC-IIA. It was shown that phosphorylation and acetylation of 
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p53 (357-382 aa) inhibits p53 DNA-binding activity (Delphin et al., 1997; Friedler et al., 2005; 
review May & May 1999). 
A link between p53-mediated transcription activation in vivo and S100A4 proteins levels has also 
been reported (Grigorian et al., 2001) and furthermore, S100A4 promote p53-dependent apopto-
sis (Naaman et al., 2004; Pedersen et al., 2004; Mahon et al., 2007) through upregulation of Bax 
(Grigorian et al., 2001) just as S100B has indicated (Scotto et al., 1998). Based on that, S100A4 
could function as an alternative regulator of p53 that circumvent phosphorylation and/or acetyla-
tion events. 
Nuclear accumulation of p53 possibly influenced by S100A4
Moreover, p53-S100A4 or p53-S100B complexes might be important in regulation of p53 sub-
cellular localization (Baudier et al., 1992; Fernandez-Fernandez et al., 2005; review Liang & 
Clarke 2001). This is plausible since S100A4 or S100B could mask the NLS and NES sites on p53 
through their binding (Fig. 27). Studies reveal that the p53 monomer enters the nucleus (Stommel 
et al., 1999; Liang & Clarke 2001; Gama-Carvalho & Carmo-Fonseca 2001), which could link 
S100A4 to a regulative role on p53 trafficking through promotion of p53 monomers. The most 
important p53 nuclear localization signal (NLS-1 305-322 aa) has very low S100A4 affinity (Fern-
andez-Fernandez et al., 2005), so import is probably not impaired by S100A4. However, S100A4 
binding of p53 is likely to mask the NES region (340-351 aa) and the S100A4-p53 complex could 
therefore promote longer nucleus retention time. A stronger p53 nuclear accumulation, promoted 
by extracellular S100A4, has recently been shown in fibroblast-like cells taken from synovial fluid 
of the inflammatory disease rheumatoid arthritis (Klingelhöfer et al., 2007). 
Normally S100A4 are located in the cytosol and the perimeter near the nucleus (Mandinova et al., 
1998; Orre et al., 2007) and could perhaps translocate to the nucleus in response to cellular stress, 
e.g. DNA damage, just like p53 (Tweddle et al., 2003). 
We hypothesise, S100A4 promote p53 translocations to the nucleus or perhaps co-translocate, 
accordingly to cellular stress. Recently, the normally nuclear S100A6 protein has been shown to 
translocate to the cytosol after post irradiation. The re-localization could be dictated by calcium 
and reactive oxygen species (ROS), which wt-p53 is known to enhance the cell-production after 
irradiation (Orre et al., 2007). S100A4 could have the reverse effect, changing the sub-cellular 
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localization to the nucleus. Here the tumor suppressor p53 could be affected by S100A4, which 
might be an important link for S100A4 induced metastasis. 
Difference in regulation of mutated p53-forms, typical found in cancer, could also be a key factor. 
For instance, mutated p53 might be more prone for S100A4 regulation, reducing p53-depend-
ent apoptosis (pro-survival), contributing to even more aggressive tumor phenotypes over time 
through wt-p53 depletion. 
CONCLUSION
Our exploration of S100A4 protein-protein interactions in vivo, carried out after cloning altera-
tions of the original protein translocation system (Knauer et al., 2005), revealed to redundant 
S100A4 bindings for practical use, at least for this established biosensor system. This we conclude 
from controls experiments, showing S100A4 has affinity for the RevM10BL-BFP protein that was 
used as fluorescence marker in fusion with S100A4-target protein fragments p53, MHC-IIA and 
liprin b1. 
Based on in vitro studies, we provide evidence that a putative common S100A4 binding interface 
(amino acid residues SLKS/N
K/D) is involved in p53 and MHC-IIA binding by S100A4. The bind-
ing is calcium dependent and site-directed mutations in the proposed S100A4 binding sites of p53 
(LKS to PGA369-371) and of MHC-IIA (SLK to APM1917-1919) reveals impaired S100A4 binding af-
finity. Additional analyses of interactions between S100A4 and p53 C-terminal deletion mutants 
supports the importance of the proposed binding site on p53 (369-372 aa) and the strongest bind-
ing is within the last 37 amino acid residues (356-393 aa), though upstream amino acid residues 
are needed for sufficient binding stability.
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SUPPLEMENTARY I - CO-TRANSFECTIONS
Co-localization of the biosensors NLS-GFP-GST-NES and RevM10BL-BFP
Co-localization of GFP-GST-NES and RevM10BL-BFP in Cos-7 cells nucleolis indicate that non-
specific interactions exist between the two biosenors that could indicate BFP:GFP dimerisation 
(Fig. I).
GFP
BFPNA
GFP
GFP
GFP
Merge BFP
Fig. I. GFP and BFP biosensors without prey or target inserts expressed in Cos-7 cells. Fluorescence microscopy 
pictures of GFP-GST-NES + RevM10BL-BFP and GFP-GST-NES alone. The fixated Cos-7 cells on coverslips were 
magnified 40x and the picture from the green and the blue channel was merged (blue color was exchanged to red color 
for better visualisation of co-localization, indicated as yellow/orange).
Co-localization of NLS-GFP-GST-S100A4-NES and RevM10BL-BFP in Cos-7 cells
Co-expression of pS-GFP-GST-S100A4-NES and pN-RevM10BL-BFP revealed similar observa-
tion of GFP:BFP accumulation as shown above in nucleolis (Fig. II). 
BFPNA
GFP S100A4 GFP S100A4
GFP GFPMerge BFP
Fig. II. pS-GFP-GST-S100A4-NES and pN-RevM10BL-BFP co-expressed in Cos-7 cells. The fixated Cos-7 cells 
were magnified 40x and the picture from the green and the blue channel was merged (blue color was exchanged to red 
color for better visualisation of co-localization, indicated as yellow/orange).
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Co-expression of pS-GFP-GST-S100A4-NES and pN-targets-BFP in Cos-7 cells
The first generated S100A4 shuttle biosensor, NLS-GFP-GST-S100A4-NES, did not co-localize 
better with S100A4 targets in nucleolis (Fig. III) than the RevM10BL-BFP control (see Fig. II).
GFP S100A4
BFPNALiprin
GFP S100A4
BFPNAp53
GFP S100A4
BFPNAMHCIIA
GFP Merge BFP
GFP Merge BFP
GFP Merge BFP
Fig. III. Co-expresission of GFP-GST-S100A4-NES and different N-terminal targets BFP-biosensor. Upper 
panel shows the GFP-GST-S100A4-NES + pN-p53-RevM10BL-BFP, the middle shows GFP-GST-S100A4-NES + 
pN-MHCIIA-RevM10BL-BFP and below shows GFP-GST-S100A4-NES + pN-Liprin b1-RevM10BL-BFP. 
Co-transfections of pS-AcGFP-S100A4 shuttles and pN-BFP-target vectors
Figure IV represents examples of fluorescence microscopy pictures taken of Cos-7 cells, express-
ing p53-RevM10BL-BFP target proteins and the respective AcGFP shuttle proteins. The AcGFP-
GST-NES-S100A4 co-localize with high quantity to the p53-RevM10BL-BFP target in nucleolis, 
whereas this is less observed for the AcGFP-S100A4-NES shuttle, possibly due to no free acces-
sible S100A4 C-terminal. This reduced target binding affinity was observed as well for the MHC-
IIA and liprin b1 targets (Fig. V). The co-localization is however similar or less in nucleolis in 
comparisons to the RevM10BL-BFP controls (see Fig. 21).
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GFP Merge BFP
GFP Merge BFP
AcGFP S100A4
BFPNAp53
AcGFP S100A4
BFPNAp53
Fig. IV. Co-transfections of p53-BFP and different AcGFP shuttle vectors in Cos-7 cells. Fluorescence micro-
scopy pictures from co-transfections showing above p53-RevM10BL-BFP + AcGFPGST-NES-S100A4 and below 
p53-RevM10BL-BFP + AcGFP-S100A4-NES. The fixated Cos-7 cells on coverslips were magnified 40x and the 
picture from the green and the blue channel was taken independently and merged, in which yellow/orange indicates 
co-localization (blue was exchanged to red color for better visualisation of co-localization).
AcGFP S100A4
BFPNALiprin
AcGFP S100A4
BFPNAMHCIIA
GFP Merge BFP
GFP Merge BFP
Fig. V. Co-expression of pS-AcGFP-S100A4-NES and pN-MHC/Lip-RevM10BL-BFP in Cos-7 cells. Fluores-
cence microscopy pictures from co-transfections showing above AcGFP-S100A4-NES + MHC-RevM10BL-BFP and 
below AcGFP-S100A4-NES + Lip-RevM10BL-BFP. Cos-7 cells on coverslips were magnified 40x. Each picture 
from the green and the blue channel was taken independently and merged, in which yellow/orange indicates co-lo-
calization (blue was exchanged to red color for better visualisation of co-localization).
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SUPPLEMENTARY II - TRANSFECTIONS OF BFP BIOSENSORS
Single transfections of previous constructed N-terminal BFP-bait vectors (by Jörg Klingelhöfer) 
shows nucleoli localization, especially for p53-BFP and the BFP control (Fig. VI), while liprin b1 
and MHC-IIA targets also distributed to the nucleus . Re-cloning of target sequences to the BFP 
vector C-terminals, followed by plasmid purifications and transfections gave much lower protein 
expression levels with transfection efficiency around 5 % (examples in Fig. VI). 
 
BFPNABFPNA BFPNA Liprinp53 MHCIIA
BFP NABFP NA p53 BFP NA MHCIIA
Fig. VI. Different BFP vectors expressed in Cos-7 cells. 24 hours after transfections of BFP vectors to Cos-7 cells, 
fluorescence BFP proteins were studied by microscopy. Upper panel show p53-RevM10BL-BFP localized in the 
cells nucleoli, liprin b1-RevM10BL-BFP distributed in the cells nucleus and nucleoli and MHCIIA-RevM10BL-BFP 
localized in the cells nucleoli and in the perimeter of the nucleus membrane. Lower panels illustrates the BFP C-ter-
minal fusion proteins; BFP-RevM10BL-p53, BFP-RevM10BL-MHCIIA and BFP-RevM10BL. These were poorly 
expressed, just as BFP-RevM10BL-liprin b1 (not shown), and bleached very quickly but showed nuclear/nucleoli 
localization. Pictures were monitored at 10x, 20x and 40x objectives. 
To resolve this, we tried to improve the DNA purity of plasmids by two different midi-prep plas-
mids preparation kits (Qiagen & Nucleobond). Nevertheless, after testing several midi-preps, cell 
expression of the vectors BFP-RevM10BL-p53, BFP-RevM10BL-Myo, BFP-RevM10BL-Lip 
and BFP-RevM10BL were still to low to fulfil the demands for co-transfections (multiple cells 
expressing both shuttle and target vectors). An endotoxin free maxi-prep kit (JetStar) was also 
tested as well, to avoid unwanted inflammatory responses from DNA plasmids contaminants prior 
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to fluorescence microscopy studies. Unfortunately, this did not improve vector expression in Cos-
7 cells either.
Test of induced apoptosis by BFP-C-terminal targets
Previously, the C-terminal of p53 (aa 361-380) has been reported to induce p53-dependent apop-
tosis in cells (Rosal et al., 2005). To insure the cytotoxic effects did not originate from the BFP-
fusion proteins themselves, we examined Cos-7 cells for cell apoptosis 20 hours after plasmids 
transfections. 
From the test we did not find indications that cells induced apoptosis after expression of any 
of the different BFP C-terminal vectors (Fig. VII) with comparison to the N-terminal targets. 
Apoptotic cells
control
p53-BFP
             
MHCIIA-BFP BFP-p53 Staurosporine
(control)
BFP-MHCIIAp53-BFP
%
25
15
20
5
10
30
4.7 % 3.9 %
8.4 %
24.4 %
5.8 %
 % Apoptotic cells 24 hours after transfections
Fig. VII. Apoptosis cell analysis 20 hours after transfections of DNA plasmids. The expressing of different BFP 
fusion proteins were confirmed by fluorescence microscopy and the cells were fixated and stained with Hoechst 33342 
(5 µg/ml). The pictures show examples of normal staining (p53-RevM10BL-BFP) and staining of apoptotic cells, 
induced by staurosporine (positive control). Apoptosis was indicated by DNA fragmentation and/or nuclear condensa-
tion in cells. Fluorescence cells were monitored by microscopy, using FITC filter and 20x zoom. The table represents 
more than 200 cell counted, showing no signs of increase apoptosis tendency for BFP-RevM10BL-p53/MHC com-
pared to the same N-terminal BFP targets.
The few observed fluorescence expressing cells of BFP C-terminal targets, seems therefore not to 
cause cytotoxic effects that induce cell apoptosis though, this experiment involves staining of all 
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cell nucleus, which could hide a small proportion of transfected apoptotic cells from detection un-
der the baseline. This analysis could therefore not give concrete answers to the expression problem 
but the reason could be because of low plasmids purity.
SUPPLEMENTARY III - S100A4 & S100B BINDING OF p53
Previously, S100B was shown to bind 40 times more tightly to the p53CT (293-393 aa) than 
S100A4 (Fernandez-Fernandez et al., 2005). We also found a similar correlation in Far-Western 
blots with the p53CT (293-393 aa) fusion protein (Fig. VIII). This study also indicated opposite 
S100A4/B affinities for p53D30, which could indicate different nearby binding sites. 
anti-S100A4
               p53CT    p53D30    
ng/well  250  50   500  250  
anti-S100B
16
               p53CT    p53D30    
ng/well  250  50    500  250  
16
A B
Fig. VIII. Far-Western blots with S100A4 or S100B overlay on p53CT and p53D30 fusion proteins. A+B lower 
panels shows Amido black staining of PVDA membranes, indicating the transferred protein fragments p53CT (250 
and 50 ng/well) and p53D30 (500 and 250 ng/well). The upper panels reveal the X-ray film developed. For overlay 
solutions were used 2 µg/ml human S100A4 multimer for (A) and 2 µg/ml human S100B multimer for (B). For (A) 
blot we used primary anti-S100A4 antibody in a dilution of 1:4,000 and for (B) we used primary anti-S100B antibody 
in a dilution of 1:4,000.
Theoretically, p53 could be bound by S100A4 and S100B simultaneously and the S100 proteins 
could perhaps have a synergistic functional effect upon p53. To test this hypothesis, we analysed 
if binding of p53 could take place by both proteins in a competitive binding experiment using 
ELISA.
This experiment (Fig. IX) revealed that p53CT binding is competitive between S100A4 and 
S100B, since adding S100A4 or S100B protein in different concentration to S100A4 or S100B 
immobilised proteins, decreased p53CT signal detection. Moreover, it appears that S100B has bet-
ter affinity for p53CT than S100A4 due to much higher concentrations of S100A4 (appr. 10 ng) 
were needed to reduce the signal of S100B-p53CT binding to the same level as S100A4-p53CT 
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binding. Overlapping S100A4/B binding sites on p53 seems therefore to exits rather than possible 
binding sites next to each other. 
Binding of p53CT (0.25 ng/µl) by S100A4 or S100B
in presence of protein inhibitor 
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Fig. IX. p53CT binding competition between S100A4 and S100B. S100A4 and S100B multimer protein (2 µg/ml) 
were immobilized on 24 wells respectively (ELISA 96-plate, greener Microlon), each added p53 C-terminal (0.25 
ng/µl), calcium (1 mM) in combination with the competitive protein inhibitor (S100A4 or S100B in conc. 1.25-100 
ng/well). The data-points represent averages of four measurements. For the detection of interactions we used primary 
anti-V5 antibody in a dilution of 1:12,000. The absorbance at 450 nm was measured using an ELISA reader.
APPARATURE
BioRad Fraction Collector (model 2128)
Centrifuge; 14000 rpm, 21912 x g (Sigma)
ELISA Reader & ELISA Washer Atlantis L0651 (ASYS)
ELISA shaker (Grant-Bio)
Flurometer (Invitrogen)
Incubator bacteria shaker, controlled environment (New Brunswick scientific, USA)
Microscope Axiovert S100TV; 10x, 20x, 40x (Zeiss)
NucleoCounter, cell-counter machine (Chemometec)
PCR thermal cycler machine (Eppendorf)
Thermomixer heating block (Eppendorf)
Sonicator: Vibra CellTM (Sonic and Materials Inc. Danbury CT. USA)
Ultrapure Water tab (ELGA)
UV-Visible spectrophotometer (LKB Biochrom, Ultrospec II)
X-ray film developer; X-OMAT 2000 processor (Kodak)
MATERIALS
6, 12, 24 well plates with deck glass, sterile NunclonTM D-surface (Nunc)
ABS; ammoniumpersulphate 10 % (10 g/100 ml) (Sigma)
Acryl-amide-Bis solution (29:1), 40% (w/v) (SERVA Electrophoresis GmbH)
AcTEVTM Protease 10 U/µl, cleavage of TEV (Glu-Asn-Leu-Tyr-Phe-Gln-Gly) (Invitrogen)
Agarose; electrophoresis grade (Invitrogen)
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Alkaline phosphotase Calf Intestinal (CIP) (10,000 U/µl) (New England BioLabs)
Alkaline phosphotase 10x buffer = NEBuffer 3 (New England BioLabs)
Amido Black membrane staining solution 2x (10% MetOH, 5% HAc) (Sigma)
Ampicillin (100 mg/ml)
Antibodies 
1st antibodies: 
  Anti-GFP polyclonal raised in rabbit, w.c. ~1:2,000 (Santa Cruz)
  Anti-human S100A4 monoclonal raised in mouse, w.c. ~1:4,000 (produced in our lab.)
  Anti-human S100B monoclonal raised in rabbit, w.c. ~1:4,000 (DAKO A/S, DK)
  Anti-p53 antibody mixture raised in mouse; 110 p240 +azid maj 01 (produced in our lab.)
  Anti-V5 monoclonal raised in mouse, w.c. ~1:5,000 (Invitrogen)
2nd antibodies: 
  Anti-mouse horse-radish-peroxidise (HRP) polyclonal raised in rabbit, w.c. ~1:2,000 (DAKO, DK)
  Anti-rabbit-HRP polyclonal raised in goat, w.c. ~1:2,000 (DAKO, DK)
Blocking-solution 10%; Blocking Reagent (Roche Diagnostics) in 100 mM Maleic acid, 150 mM NaCl, pH 7.5.
Blue Juice 10x, bromophenol blue gel-loading buffer (Invitrogen)
BSA, 100x 10 mg/ml (New England BioLabs)
Buffer A: Reagent A100 lysis buffer (Chemometec)
Buffer B: Reagent B stabilisation buffer (Chemometec)
Cell lines: 
 COS-7 (monkey kidney cells, passage 18)
 HeLa (uterine cervical carcinoma cells)
 MCF-7 and MCF7-51 (human breast cancer)
 VMR (liver mouse mammary carcinoma)
 NIH 3T3 (mouse embryonic fibroblast cell line)
Chloroform/isoamylalcohol 24:1 (96%:4%)
CL-eXposeTM film 5x7 inches (Pierce)
Comasive GelCode® Blue Stain reagent (Pierce)
Competent cells: 
 BL21 Star DE3 (Novagen)
 INVF’ and TOPO TOP10 (Invitrogen)
 NEB Turpo, C2984 (New England BioLabs)
Counter-cassette (Chemometec)
Cover-slips, glass thin (Agar Scientific)
DMEM (Dulbecco’s modified Eagle’s medium) with GlutaMAXTM + D-glucose (4.5 g/L) + pyruvate, supplemented 
with 10 % FBS and FIB 71 penicillin+streptomycin mix (2 ml pr. 500 ml DMEM 50 IU/ml) (all from Invitrogen).
DMSO, dimethylsufoxid (Sigma)
DNA filter; Ni-DEAE membrane 0.45 µm (Schleicher & Schuell)
DNA ladders (0.1 µg/µl); 100 bp+, 1 Kb, 1 Kb+ (Invitrogen)
DNA-Ligase (T4 DNA 400.000 Units/ml) (Invitrogen)
DNA T4 Ligase reaction buffer; 10x (New England BioLabs)
DNA polymerases: 
 VentR 2,000 U/µl (New England BioLabs)
 PfuUltraTM 2.5 U/µl (Stratagene)
 Platinium® Taq 5 U/µl (Invitrogen)
DNA sequencing; 1-2 µg DNA plasmid send to MWG Biotech Fraunhoferstr. 22, 82152 Martinsried, Germany.
DNA plasmid templates: 
 pAcGFP-golgi 1 µg/µl (Clontech)
 human liprin b1 wild type cDNA (sequenced plasmid from the laboratory))
 human MHC-IIA wild type cDNA (sequenced plasmid from the laboratory)
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 human p53 wild type cDNA (sequenced plasmid from the laboratory)
 human S100A4 cDNA (sequenced plasmid from the laboratory)
dNTPs mix: 12.5 mM dATP, 12.5 mM dGTP, 12.5 mM dCTP, 12.5 mM dTTP, pH 8.0 (Invitrogen)
D-PBS 10x GIBCOTM (+ or - CaCl2 & MgCl2) (Invitrogen)
Drummond pipet-aid
DTT 0.1 M, DL-Dithiothreitol (Sigma)
ECL Supersignal reagent (Pierce, Amersham)
EDTA 0.5 M, Ethylene diaminetetraacetic acid (Sigma)
Electrophoresis buffers: 
 1x BionicTM buffer (incl. ethidium bromide 60 µg/ml) (Sigma). 
 1x TAE buffer (0.04 M Tris-Base, 0.04 Acetate, 0.001 M EDTA, ethidium bromide 60 µg/ml)
 1x TBE buffer (0.089 M Tris-Base, 0.089 Borate, 0.002 M EDTA, ethidium bromide 60 µg/ml) (Medinova  
 Scientific A/S)
Electrophoresis Unit (Hoefer)
ELISA (Enzyme-Linked ImmunoSorbent Assay) flat-bottomed 96 wells plate (greener Microlon)
ELISA coating buffer (pH ~10, 1.6 g Na2CO3 + 3 g NaHCO3)
Elution-buffer for protein purification (100 mM NaAc, 1 M NaCl, pH 4)
Elution-buffer* for protein purification at native conditions (200 mM imidazole, 1 M NaCl, pH 11)
Eppendorf tubes (Eppendorf)
EtOH, ethanol 96% (Sigma)
Falcon 14 ml polypropylene round-bottom (Becton Dickinson)
Falcon tubes (Greiner bio-one)
FBS (Fetal Bovine Serum) (Invitrogen).
Fluoromount G, Lot J4606-XE96 (Southern Biotech)
Fluorescence microscopy filters (Chroma Technology Corp.)
FPLC Superdex 15 ml column (BioRad)
Gel-running buffer 5x (125 mM Trizma-base, 1.25 M Glycine, 0.5% SDS, pH 8.6)
Gilson pipetman (2, 20, 200, 1000 µl)
Glutathione (GST) beads, immobilized in 50% slurry B-PER® reagent, no. 78380 (Pierce)
Glycogen, 20 µg/µl (Invitrogen)
Hoechst 33342, 10 mg/ml (Sigma)
Imidazole >99%; 1,3-diaza-2,4-cyclopentadiene (Sigma-Aldrich)
Immobilion™-P (PVDF membrane Millipore, US)
IPTG 1 M (IsoPropyl b-D-ThioGalactopyranoside) (Sigma)
Kodak BioMax Cassette (Amersham)
LB media, Luria Bertani media (BD diagnostic systems). 
Lipofectamine 2000 reagent 1 mg/ml (Invitrogen)
Lysis buffer (0.5 % NP-40, protease inhibitor, 1 mM Ca2+ in 1xTBS)
Miniprep kit (Bio Rad; Eppendorf)
Midi/Maxi prep kit (JetStar 2.0 Genomed; Nucleobond extra; QIAfilter plasmid QIAgen).
NEBuffer 1, 2, 3, 4 (New England BioLabs)
Ni-NTA agarose solution (QIAgen, GmbH)
NP-40; Nonidet®P 40 substitue (Nonylphenylpolyethylene glycol) (BioChemika, Fluka)
Object glass, SuperFrost®Plus 25x75x1.0 mm (Menzel-Glaser, GmbH) 
Opti-Mem 1x: RSM (reduced serum medium) with glutamine + HEPES (Invitrogen).
Overlay-solution: 0.5 % NP-40, 0.1% Blocking-solution, 0.25 % gelatine, 100 mM NaCl, 50 mM Tris-Cl (pH 7.6), 1 
mM CaCl2 plus interacting protein of interest (10 ml solution per membrane filter).
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PCR buffer, 10x (incl. 25 mM MgCl2, 500 mM KCl, 0.01% geletin,100 mM Tris-HCL, pH 8.3) (Invitrogen)
PD-wash buffer: D-PBS (+Ca2+, +Mg2+), 0.5% NP-40
PD-wash buffer *: D-PBS (-Ca2+, -Mg2+, 5mM EDTA), 0.5% NP-40
PFA (para-formaldehyde) 4% (Sigma)
Phenol 90% (Riedel-de-Haën)
Protease inhibitor cocktail tablets, Complete EDTA-free (Roche Diagnostics GmbH)
Proteins:
 Human S100A4 multimer (4 mg/ml) (provided by Jörg Klingelhöfer)
 Human S100B multimer (3 mg/ml) (provided by Jörg Klingelhöfer)
Proteins produced in the laboratrory:
p53CT:  11.3 mg/ml, 15.08 kDa, fusion protein HisV5TEV- human wt-p53 C-terminal (293-393 aa) 
PGA:  15.8 mg/ml, 15.08 kDa, fusion protein HisV5TEV- human p53 site-directed mutant 
   (LKS to PGA369-371) C-terminal (293-393 aa) 
p53D30:  2.52 mg/ml, 11.81 kDa, fusion protein HisV5TEV-human p53D30 (293-363 aa) 
p53D37:  2.6 mg/ml, 10.91 kDa, fusion protein HisV5TEV-human p53D37 (293-356 aa) 
p53D68:  3.6 mg/ml, 7.23 kDa, fusion protein HisV5TEV-human p53D68 (293-356 aa) 
p53-Ala:  7.1 mg/ml, 8.29 kDa, fusion protein HisV5TEV-human p53-Ala C-terminal (351-393 aa) 
MHCIIA: 14.2 mg/ml, 12.92 kDa, fusion protein HisV5TEV-human wt-MHC-IIA C-terminal (1878-1961 aa) 
APM:  16.7 mg/ml, 12.92 kDa, fusion protein HisV5TEV- human MHC-IIA APM site-directed mutant 
     (SLK to APM1917-1919) C-terminal (1878-1961 aa) 
Primers
 Primers for pET151/D-TOPO expression vector cloning 
Fw human p53CT 293aa 5’-cacc GGG GAG CCT CAC CAC GAG-3’
Rev p53 393aa stop 5’-TCA GTC TGA GTC AGG CCC TTC-3’
Rev p53∆30 363aa stop 5’-TCA AGC CCT GCT CCC CCC TGG -3’
Rev p53∆68 325aa stop 5’-TCA ATC CAG TGG TTT CTT CTT TGG-3’
Fw wt-MHC-IIA 1878aa 5’-cacc CTG GAG GAG GCC GAA GAG-3’
Rev MHC-IIA 1961aa 5’-CTA TTA TTC GGC AGG TTT GGC-3’
Fw p53 Ala 5’-cacc GCC CAG GCT GGG AAG GAG-3’
Rev p53∆37 stop 5’-CTA AGC CTG GGC ATC CTT GAG-3’
 Primers for cloning of biosensors
Fw BFP-NA/NruI 5’-CACC cgc tgc ttc gcg atg ta-3
Rev BFP-NA/XbaI NheI 5’tct aga TCA cag ctc ctc gcc ctt gct agc-3’
Fw BFP/KpnI gg GGTACC AGC AAG GGC GAG G
Rev BFP/KpnI TTTT GGTACC CTT GTA CAG CTC GTCC
Fw AcGFP/NheI gg GCTAGC GTG AGC AAG GGC
Rev AcGFP/KpnI gg GGTACC CTT GTA CAG CTC ATC C
Fw Myo450/NheI a GCTAGC ATG GAG GGC ATC GTC
Rev Myo450/XbaI a TCTAGA tta TTC GGC AGG TTT GGC
Fw p53/NheI a GCTAGC CAG ATC CGT GGG C
Rev p53/XbaI aaa TCTAGA tca GTC TGA GTC AGG CC
Fw Lip/NheI a GCTAGC ATGCGCCTGTATGAG
Rev Lip/XbaI a TCTAGA  TCA AACGTTTGAGTCTTCATC
 Primers for Quick-change site-directed mutagenesis 
Fw p53-PGA/XmaI gct cac tcc agc cac ccg ggg gcc aaa aag ggt cag tct acc
Rev p53-PGA/XmaI ggt aga ctg acc ctt ttt ggc ccc cgg gtg gct gga gtg agc
Fw Myo-APM/HindIII cgc gaa atc agc gcc cca atg aac aag ctt agg cgc ggg g
Rev  Myo-APM/HindIII c ccc gcg cct aag ctt gtt cat tgg ggc gct gat ttc gcg
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QuikChangeR site-directed mutagenesis kit (Stratagene)
Restriction enzymes: AflII, BamHI, KpnI, HindIII, NdeI, NheI, NruI, SspI, XbaI, XmaI (New England BioLabs)
Resuspension-buffer (50 mM Tris, 0.2 NaCl, pH 7.6)
S100A4-sepharose beads, 5 mg/ml (provided by Jörg Klingelhöfer)
SDS+DTT 5x (250 mM Tris pH 6.8, 250 mM DTT, 10% SDS, 0.5% Bromphenylblue, 50% Glycerol)
SDS-polyacrylamide gel (8% or 15%)
SeeBlueR Plus 2 molecular weight marker; pre-stained standard 1x (Invitrogen) 
SOC medium (New England BioLabs) 
Sterile filter 0.45 µm (Sterifix, Braun)
Sulphoric acid 1 M (H2SO4) (Sigma)
Superblock 1:2; diluted in PBS -MgCl2, -CaCl2 (Pierce) 
Syringe (Ritips, Ritter medR)
T25 and T75 tissue culture flasks with filters, sterile Nunclon
TM D-surface (Nunc)
TBS stock 10x (1.37 M NaCl, 0.2 M Tris, pH 7.6)
TBS-T: 1xTBS+0.1% Tween 20
TEMED 0.72 g/ml GIBCO (Life Tecnologies) 
TEV-buffer 20x (1 M Tris-Cl pH 8 + 10 mM EDTA) (Invitrogen)
TMB (3,3’,5,5’-tetrametylbenzidine <0.05%, hydrogen peroxide) (KEM-EN-TEC Diagnostics)
TOPO®-vector for PCR products: pCR®II-TOPO®, 10 ng/µl (Invitrogen)
Trypsine (FIB 72 x 0.25 trypsine + EDTA) GIBCO (Invitrogen)
Tween 20 (Sigma)
X-gal, 5-bromo-4-chloro-3-indolyl-b-D-galactopyranoside (40 mg/ml) in dimethylformamide (DMF)
Vectors
     Shuttle/prey-Vectors:
 p3_NLS-GFPGST-Jun-RevNES     0.5 µg/µl (02)
 pS-GFPGST-S100A4-NES      0.5 µg/µl (03)
 pS-GFPGST-NES      0.8 µg/µl (15)
 pS-EGFPGST-S100A4      1.4 µg/µl (44)
 p-AcGFP1-golgi (Clontech)     0.3 µg/µl (84)
 pS-AcGFPGST-NES-S100A4     2.0 µg/µl (85)
 pS-AcGFP-S100A4-NES      0.6 µg/µl (86)
     Bait-Vectors (nucleus/nucleoli localization):
 pc3-Max-RevM10BL-BFP      0.25 µg/µl (01)
 pN-RevM10BL-BFP      1.0 µg/µl (14)
 pN-Myo-RevM10BL-BFP      0.8 µg/µl (08)
 pN-p53-RevM10BL-BFP      1.0 µg/µl (04)
 pN-Lip-RevM10BL-BFP      0.8 µg/µl (09)
 pN-S100A4-RevM10BL-BFP     0.8 µg/µl (06)
 pN-BFP-RevM10BL-BFP      0.15 µg/µl (72)
 pN-BFP-RevM10BL-p53 (wt-p53CT, 331-393 aa)  0.6 µg/µl (77) 
 pN-BFP-RevM10BL-MHCIIA (wt-MHCIIA-CT, 1855-2021 aa) 0.6 µg/µl (74) 
 pN-BFP-RevM10BL-Lip (wt-Liprin b1, 941-1006 aa)  0.6 µg/µl (80) 
 pN-RevM10BL-RFP      0.7 µg/µl (47)
Wash-buffer for protein purification (50 mM Tris, 1 M NaCl, pH 7.6)
Wash-buffer* for protein purification at native conditions (10 mM imidazole, 1M NaCl, pH 8.5)
Whatmann 3 MM paper (Millipore)
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METHODS 
DNA cloning procedures
DNA gel- electrophoresis
1 gram agarose was added to either 100 ml Bionic, TAE or TBE buffer. After heating the agarose gel-solution (avoid 
boiling), it solidified in an electrophoresis chamber with pocket-forming combs (approximately 30 min). DNA in 1x 
Blue Juice loading buffer (Invitrogen) were loaded on gel. TAE or TBE buffer was used depending on DNA fragments 
sizes (TAE for large and TBE for short DNA fragments) and electrophoresis was run at max 40 Volts together with 5 
µl DNA 1Kb+ ladder (Invitrogen) as reference. The Bionic buffer was used when having multiple fragment sizes and 
DNA-electrophoresis separation was run at max 50 Volts.
LB plates
500 ml LB-agar medium was autoclaved for 20 min (121ºC) and after the temperature had dropped to about 50ºC, 
500 µl ampicillin (100 mg/ml) was added. The bottle was shocked and about 20 ml LB media was added for each 
Petri dish. For blue-white screening, LB-media plates were added with additional 80 µl X-gal (40 mg/ml) and 20 mM 
IPTG prior to plating of bacteria. 
PCR
DNA products were produced by PCR from cDNA templates: pAcGFP-golgi (Clontech); human liprin b1 cDNA 
(plasmid from the lab.); human MHC-IIA (plasmid from the lab.); human p53 wt cDNA (plasmid from the lab.); 
human S100A4 cDNA (plasmid from the lab.) or from other DNA plasmids (e.g. shuttle/bait vectors) stored in the 
laboratory.
Design of primers for the PCR reaction was derived with the Vector NTI Advance 10 program (Invitrogen). The prim-
ers were generally designed to fulfil following criteria: length of residues ~ 15-22 bp, GC contents 40-60%, 2-4 GC in 
the 5’end of the primer (due to stronger binding) and a Tm ~52-62ºC (primers then most ideal). Primers were ordered 
from TAG Copenhagen A/S, Denmark (http://www.tagc.com/).
PCR reaction mixture
 DNA template (10-100 ng)    1 µl
 10x PCR buffer     5 µl
 50 mM dNTPs    0.5 µl
 PCR primers (0.05 µg/µl each)   1 µl
 Sterile water to a final volume of    49.8 µl
 Platinium® Taq DNA polymerase (5 Unit/µl)  0.2 µl
 
The 50 µl PCR reaction mixture was placed in a PCR tube and run in the PCR machine at following program: 
 25x cycles: 1 min 94ºC (denaturation), 1 min 55ºC (annealing), 1 min 72ºC (extension) 
 1x cycle: 7 min 72ºC (final extension) 
A control PCR reaction mixture, lacking DNA template, was run parallel as a negative control and successful DNA 
amplification was confirmed by DNA gel-electrophoresis (10 µl PCR product per lane). 
Directed PCR-cloning
By using the cloning kit from Invitrogen (TOPO TA cloning / Version R, 8 Apr. 2004, 25-0184) PCR products were 
cloned into the TOPO®-vector. The method was based on a direct insert of PCR product into the lacZa gene in the 
vector. This method enabled blue-white screening of bacteria without or with PCR inserts (blue or white respectively). 
The cloning was done as following:
The used TOPO® linearized vector had single overhanging 3’deoxythymidine (T) residues and by using Platinium® 
Taq DNA polymerase in the PCR mixture, a single deoxyadenosine (A) were added to the 3’ ends of the PCR prod-
ucts. Since the TOPO® vector contained covalent bound topoisomerase I, the fresh PCR product added (0.5-4 µl) to 
the TOPO®-vector (1 µl) could ligate efficiently at room temperature within 5 minutes (no DNA ligase needed). The 
ligated vector could then be transformed into competent cells (method follows below). After incubation in shaking 
SOC medium at 37ºC for 1 hour, the bacteria were plated on a LB plate with ampicillin (vector AmpR) plus 40 µl X-gal 
(40 mg/ml) and incubated overnight at 37ºC. White colonies (or light blue) were picked for plasmid DNA isolation 
(mini-prep), followed by restriction or sequencing analysis to confirm presence of PCR insert.
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PCR reaction for site-directed mutagenesis 
The QuikChangeR site-directed mutagenesis kit (Stratagene) was used. 
Primers were designed to fulfil following criteria: Both primers should contain the desired mutation and anneal to the 
same sequence on opposite strands of the plasmid. Length of residues 25-45 bp. GC contents minimum 40%, ~10-15 
bp correct sequence on each side of the primer and one or more G or C in each end of the primer. Tm over 78ºC and 
calculated after the formula below and %-values in whole numbers: 
 Tm= 81.5 + 0.41(%GC) – 675/nucleotides of primer - % mismatch
Primers were ordered from TAG Copenhagen A/S, Denmark (http://www.tagc.com/).
PCR QuikChange reaction mixture
 dsDNA template (5-50 ng)   X µl
 10x reaction buffer   5 µl
 dNTP mix    1 µl
 PCR primers (125 ng of each primer)  X µl
 Sterile water to a final volume of   50 µl
 PfuTurbo DNA polymerase (2.5 Unit/µl)  1 µl
The templates for PCR QuikChange reaction mixture were added to PCR tubes and PCR was done using following 
program: 
 1x cycle: 30 sec 95ºC
 12-18x cycle: 30 sec 95ºC, 1 min 55ºC, 1 min/kb of plasmid length 68ºC.
A control PCR reaction mixture (using pWhitescript DNA plasmid control and control primers #1+#2), was run 
parallel in the PCR machine as a negative control and successful DNA amplification was confirmed by DNA gel-
electrophoresis.
To each PCR tube with amplified DNA plasmids was added 1 µl Dpn I restriction enzyme (10 U/µl) and at 37ºC, the 
tubes were incubated for DNA digestion over 1 hour (specific digest of parental DNA plasmid template when isolated 
from a Dam+ bacteria strain). For transformation, XL1-Blue super competent cells were thawed on ice and to separate 
aliquots of 50 µl competent cells were added 1 µl DNA plasmid (from Dpn I-digested solutions of reaction and control 
samples respectively). 
After standard transformation procedure was completed (see method later), cells were spread on agar plates (AmpR) 
for blue-white screening and incubated at 37ºC overnight. The following day, blue colonies between 10-1000 colonies 
were obtained as result of site-directed mutation replacement. For the control, 80% of the colonies should appear as 
blue colonies (about 50-800 colonies). 
Restriction of DNA plasmids or PCR product
To a solution of 0.5-1 µg DNA plasmid or PCR product was added: 
 2 µl restriction buffer (NEB-Buffer; New England Biolabs)
 0.2 µl BSA (if needed; New England Biolabs)
 1 µl of each restriction enzyme (New England Biolabs)
 X µl H2O to a final volume of 20 µl
Restriction was carried out in a thermomixer at 37ºC for at least 30 min (alternatively overnight).
After 30-45 min restriction of vectors (cut for directed DNA fragment insertion), dephosphorylation of the vectors 
were performed by adding 2 µl NEB 3 buffer and 0.5 µl alkaline phosphotase and incubate additionally 15 min at 
37ºC. 
Purification of dephosphorylated vector or DNA fragments
To each restriction solution, 2 µl loading buffer (10x Blue Juice) was added and DNA was separated on a 1% agarose 
gel by DNA gel-electrophoresis. DNA was purified by running DNA fragments or DNA dephosphorylated vector 
onto a DNA filter Ni-DEAE membrane (Schleicher & Schuell) placed in the agarose gel. The filters with DNA was 
added to 200 µl 1.5 M NaCl and DNA were released by placing the solution in a heating block at 70ºC for 15 min. The 
DNA solution was added to 2.5 x volume 96% EtOH with 1 µl glycogen and left for 5 min in dry ice + 96% EtOH 
(alternatively at -80ºC for 30 min). The solution was centrifuged for 20 min (21000xg, at 4ºC) and after removing the 
supernatant, the pellet was washed with 200 µl 70% EtOH, followed by 5 min centrifugation (21000xg, at 4ºC). The 
solvent was removed carefully and the DNA pellet was dried under vacuum at 25ºC and re-suspended in H2O. DNA 
was stored at -20ºC.
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Phenol/chloroform DNA purification
A 40 µl DNA solution (e.g. PCR product) was added to an Eppendorf tube with 200 µl phenol and 160 µl H2O (1:1 
volume) and centrifuged 8 min at room temperature (14,000xg). The water-phase, containing the DNA, was carefully 
removed from the upper phase and added to a new Eppendorf tube. 200 µl chloroform (CHCl3) was added and the 
tube was centrifuged additionally 8 min at room temperature (21,000xg). The water phase was carefully collected and 
added to 2.5 x volume ethanol, followed by DNA purification as described above.
Ligation of dephosphorylated vectors and DNA fragments
Ligation mixtures were prepared as following: 
 2 µl DNA ligase buffer (New England BioLabs)
 y µl dephosphorylated vector (~50-100 ng)
 x µl DNA insert fragment (~10-50 ng)
 20-(2.5+x+y) µl H2O
 0.5 µl DNA-Ligase (400.000 Units/ml)
Each mixture was kept at room temperature for 1 hour or overnight at 14ºC before storage at -20 ºC. A control liga-
tion mixture with no DNA insert was run simultaneously to evaluate amount of false positive after transformation of 
ligated vectors to competent cells.
Transformation of competent cells
Competent cells (e.g. NEB Turpo, New England BioLabs) were trawn on ice. 10 µl ligated vector mixture (vector+DNA 
fragment insert) was added to 20 µl competent cells and kept on ice for 20-30 min. The cells were heat shocked 30 
seconds at 42ºC (water bath) and placed on ice 2-3 min. 250 µl SOC medium was added and the tube was agitated 
(200 rpm) for 1 h at 37ºC. The bacteria cells were plated on LB plates with a selective antibiotic (e.g. kanamycin or 
ampicillin depending on the vector used) and incubated overnight at 37ºC.
Purification of DNA plasmids
For mini-prep DNA plasmid preparation, one bacteria colony was picked from a LB plate and inoculated in 4 ml LB 
media plus a selective antibiotic (4 µl ampicillin 100 mg/ml) overnight with rigorous shaking (200 rpm) at 37ºC. For 
midi or maxi-prep were used instead 50/200 µl bacteria glycerol stock to 100-200/500 ml LB media. Before DNA 
plasmid purification, a glycerol stock was prepared and stored at -20ºC (250 µl bacteria solution and 250 µl steri-
lized glycerol). The DNA plasmid purification procedures were carried out from grown bacteria cultures according 
to manufactures protocols: Mini-prep kit (Bio Rad, Eppendorf), Midi/Maxi-prep kit (Nucleobond extra, QIAfilter 
plasmid, JetStar 2.0 Genomed).
Sequencing
1-2 µg DNA plasmids were dried and send for sequencing (MWG Biotech, Germany).
PCR-cloning into pET151/D-TOPO expression vector
The method was used to insert cDNA (PCR product) in an expression vector to produce fusion proteins, using the 
ChampionTM pET Directional TOPO® expression kit (Version G, 28 Jan. 2004, 25-0400, Invitrogen). 
PCR products were first produced and from PCR reaction mixture solution was added 0.5 µl to the TOPO vector (1 
µl). After ligation at room temperature for 10 minutes (no ligase needed), the vector was transformed into TOPO 
TOP10 competent cells and bacteria were grown on LB+AmpR plates (method above). To confirm presence of PCR 
insert, restriction analysis with SacI + NdeI restriction enzymes were performed on purified DNA plasmids (after 
mini-prep DNA purification). Correct clones (insert + 111 bp basepairs from empty vector) were verified by DNA 
fragment size after running DNA gel-electrophoresis. Plasmids of clones with expected DNA-inserts were dispatched 
for DNA sequencing for final documentation. Correctly cloned expression vectors were then transformed into BL21 
Star(DE3) E. coli competent cells to carry out protein production.
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Protein production & purification
BL21 bacteria, containing the pET151 expression vector with the inserted cDNA PCR-fragment were inoculated in 
1 L LB media (2% w/v from bacteria glycerol stock) and grow overnight at 37ºC at 200 rpm. The following day at 
OD600 = 0.7-1.0, the bacteria were induced with 1 mM IPTG. After growing 2-3 hours, the bacterial pellet was har-
vest at 4,000xg for 15 min at 4ºC. The pellet was dissolved in re-suspension buffer to a total volume of 20 ml. To the 
suspension was added protease inhibitor, the solution was transferred equally to 2x15 ml tubes and each tube was 
sonicated 4x30 seconds on ice. The cell-suspension was adjusted to 1 M NaCl and centrifuged at 20,000 x g for 20 
min at 4ºC in 2 ml Eppendorf tubes. The supernatant was collected and filtrated (0.45µm sterile filter). 2 ml Ni-NTA 
(QIAgen) was prepared to remove isopropanol from the suspension by washing 3 times with Wash buffer through a 
20 ml Bio Rad column filter. The Ni-NTA and the filtrated supernatant were placed on a tumbler overnight at 4ºC in 
a 50 ml Falcon tube. 
The next day, affinity chromatography was carried out using a fast protein liquid chromatography (FPLC) apparatus 
from Bio Rad (model 2128).
The protein solution on a 15 ml FPLC glass column (Bio Rad) was washed with 1 ml/min wash buffer (35 min) and 
the chromatography profile was monitored for absorbance at 280 nm. After washing, proteins were eluted with 1 ml/
min elution buffer in 1.5 ml fractions at OD280>0.1. The collected fractions were adjusted with salt (up to 1M NaCl 
dependent on protein) and pH = 7.6. Protein concentrations were measured by a UV-Visible spectrophotometer or a 
Flurometer (Invitrogen). Aliquots of 100 µl were made and stored at -80ºC after snap freezing in liquid nitrogen.
Note several attempts to purify MHC-IIA and the APM mutant by the elution buffer (100 mM NaAc, 1 M NaCl, pH 
4) gave poor yields. By using wash buffer* and elution buffer* (200 mM imidazole, 1 M NaCl, pH 11), the yield im-
proved remarkably and harvested elution contained approximately 15 µg/µl protein concentrations.
TEV- cleavage of fusion proteins
One unit of AcTEVTM protease cleaved over 85% of 3 µg substrate in 1 hour at 30°C (Invitrogen). AcTEV recognizes 
the TEV nuclease restriction site (Glu-Asn-Leu-Tyr-Phe-Gln-Gly) and was used to cleave the TEV site in the fusion 
p53 and MHC-IIA proteins, removing the polyHis-V5-TEV fragment. 
100 µg fusion proteins were incubated for 5 hours at 25°C within 100 µl water containing 1xTEV buffer, 0.1 M DTT 
and 10 units of AcTEVTM protease. After restriction, the cleaved proteins were stored at -20ºC.
ELISA protocol
Wells on the ELISA 96-well plate (greener Microlon) was calibrated with S100A4 multimer protein (2 µg/ml) in 50 
µl ELISA coating-buffer. After 2 hours at room temperature, the coating-buffer was discarded from the plate and the 
immobilised S100A4 was washed once with 300 µl TBS-T (using an ELISA washer). To each well, 200 µl 1:2 Super-
block was added and left for 1 hour at room temperature (shorter time was possible). The superblock was discarded 
and the wells were washed again with TBS-T. 50µl protein solution (0.001-125 ng/µl diluted in 1:5 superblock) was 
added to each well in different diluted concentrations. The ELISA plate was incubated at 4°C overnight with slow 
agitation. Next day, the wells were washed 4 times with TBS-T, 50 µl primary anti-V5 (Invitrogen) antibody solutions 
(diluted 1:12,000 in 1:5 superblock) was added and the plate was kept at 30°C with agitation for 1 hour. The plate was 
washed 4xTBS-T, 50 µl secondary anti-mouse (DAKO) antibody solutions (diluted 1:3000 in 1:5 superblock) was 
added and kept at 30°C with agitation for 1 hour. The plate was washed again 4xTBS-T and 100 µl TMB (KEM-EN-
TEC Diagnostics) was added to each well (NB! the TMB solution should be 20-25°C). The plate was placed in dark 
for 1-15 min. The reaction was stopped by adding 100 µl H2SO4 (1M) to each well. The ELISA plate was measured at 
450 nm in an ELISA reader (ASYS). 
For ELISA wells containing an EDTA control test, all procedure steps were done with addition of 25-30 mM EDTA. 
Additionally, standard controls were performed of diluted p53 protein concentrations were performed in triplicates by 
immobilize the proteins directly in to empty ELISA wells. After 2 hours incubation in 50 µl coating-buffer, washed 
once with 300 µl TBS-T and 1 hour incubation in 200 µl 1:2 Superblock, these wells could be incubated overnight 
and developed the next day.
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Pull-down experiments
For S100A4 pull-down experiment (PD) we used human recombinant his-tagged S100A4 coupled to sepharose beads 
(5 mg/ml) via primary amines (produced in the laboratory). For GST pull-down we used immobilized Glutathione-S-
transferase (GST) beads, in a 50% B-PER® slurry (Pierce).
125 µg/µl S100A4-sepharose beads were incubated together with approximately 50-500 ng fusion protein (e.g. poly-
HisV5TEV-p53 C-terminal) in a 1 ml PD-wash buffer solution. The solution was incubated with agitation for 1 hour at 
room temperature or overnight at 4°C. The tube was centrifuged 15 sec at 13,400g and the supernatant was collected 
as a control. The remaining pellet was washed 4 times with PD-wash buffer and in between each step; the tube was 
shaking 3 minutes, centrifuged 15 sec (13,400g) and supernatant removed. After last washing step, the tube was cen-
trifuged additionally 30 sec and remaining liquids were removed with a 200 µl pipette. 100 µl 1xSDS+DTT was added 
to the beads and the solution was boiled for 2-3 min, centrifuged 10 sec and was ready for Western blot analysis. 
EDTA control tests were carried out throughout the procedure with PD-wash buffer* (D-PBS -Ca2+, -Mg2+, 5mM 
EDTA, 0.5% NP-40).
For PD of fusion-protein cell extracts, GST-beads were prepared by washing the beads two times with 1xTBS and 
diluted in a 1:1 ratio. To each protein solution was added 60 µl GST-beads solution and incubated 10-20 min at room 
temperature (shaking). The coupled GST-beads with fusion-proteins were centrifuged (8,000 rpm, 15 sec) and the 
beads were washed 3 times with 200 µl 1xTBS (each step with 2 min shaking, centrifugation and solvent removal). 
To GST-bead pellets, 60 µl 1xSDS+DTT were added and stored at -20°C until Western blot analysis could be per-
formed. 
Western blotting
SDS-polyacrylamide gel (15%) was prepared as following (for 2 gels): Gel-sealing was made from 4 ml 10-15% 
acryl-amide gel solution, 40 µl ABS and 4 µl TEMED and placed to the bottom of the gel-form for 10-15 min.
Each separation gel was prepared from 6.2 ml 15 % Acryl-amide gel solution (5.27 ml H2O, 5.625 ml 40% Acryl-
amide, 3.8 ml 1.5 M Tris pH 8.7, 0.15 ml 10% SDS, 0.15 ml ABS, 6 µl TEMED), overlaid with 1 ml H2O and polym-
erized for 30 min. 4 ml stacking-gel 5% solution was prepared, containing 2.92 ml H2O, 0.5 ml 40% Acryl-amide, 
0.5 ml 1.0 M Tris pH 6.8, 40 µl 10% SDS. The electrophoresis unit was assembled, 40 µl ABS and 4 µl TEMED was 
added to the stacking solution and applied on top of the gels followed by a well-forming plastic comb. 
Using sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE), protein samples were loaded on the 
SDS-polyacrylamide gel (15 % gel) in 1xSDS+DTT loading buffer, after boiling 2 min at 95°C and a short centrifuga-
tion. The samples were run with a SeeBlueR Plus 2 (Invitrogen) molecular weight marker (7 µl) at 120 Volts in 1xGel-
running buffer. After 1-2 hours, the proteins were transferred onto a PVDA membrane (Immobilion™-P Millipore) 
using a Semi-dry System. Procedure: The Immobilon membrane was cut according to gel size and added date with 
a pen. The membrane was placed in 96% EtOH for a few minutes and then wetted in 1xBlotting buffer. The blotting 
sandwich was assembled with 2x4 pieces of Whatmann 3MM paper, wetted in 1xBlotting-buffer that constituted a 
sandwich around the acrylamide gel that was applied on top of the PVDA membrane. The blotting was run according 
to manufacturer’s instructions for approximately one hour at 200 mA. After blotting, the PVDA membrane was rinsed 
briefly in water and the molecular weight marker on the PVDA membrane was marked with a pen. The proteins were 
stained by incubating the membrane in 50 ml Amido Black solution (5 % Acetate/10 % Methanol/250 µl Amido Black 
stock) for about 2 minutes. Afterwards the membrane was scanned for documentation. 
Far-Western blotting (or else jump to development of Western blotting):
The PVDA membrane was blocked for 1 hour at room temperature in 50 ml 1% Blocking-solution and then trans-
ferred to an overlay-solution containing possible interacting proteins (e.g. polyHisV5TEV-p53 C-terminal). Over-
night, the PVDA membrane with overlay-solution was kept at 4°C with agitation. The next day, the PVDA membrane 
was washed two times in 1xTBS-T and two times in 1xTBS (50 ml each time).
Development of Western blot: The PVDA membrane was blocked for 30-60 min in 1 % Blocking-solution and then 
incubated in 0.5% Blocking-solution with primary antibody on a rocking platform for 1 h at room temperature. The 
PVDA membrane was washed again two times in 1xTBS-T, two times in 0.5% Blocking-solution (50 ml each time) 
and incubated with secondary antibody in 0.5% Blocking-solution for 45-60 min at room temperature. 1 ml ECL Su-
persignal reagent (Amersham) was prepared per 8x8 cm PVDA membrane and kept in dark while washing four times 
5 minutes with 1xTBS-T. The ECL supersignal was added onto the PVDA membrane, kept in dark for 3 minutes and 
the membrane was placed in a Kodak BioMax Cassette for film development. This was achieved in dark room using 
an auto X-ray developer and X-ray films (CL-eXposeTM, Pierce). Generally short expositions from few seconds to a 
few minutes were needed.
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In vivo cell culturing
All cell cultures were maintained in T75 flasks at 37°C in a humidified 95% air and 5% CO2 atmosphere. To create 
optimal growth conditions the Dulbecco’s modified Eagle’s medium (DMEM) was changed every 2-3 days and cells 
were split to prevent stress, when reaching confluence levels. 
Splitting cells
All medium was removed gently from the T75 flask and washed with 10 ml 1xD-PBS (- CaCl2 and - MgCl2). The PBS 
was removed, 1 ml trypsine was added and the cells were incubated 3-4 min at 37°C to detach the cells from the sur-
face. 3 ml DMEM medium was added (pipette up and down) and 0.5 ml was left remaining (1/8 splitting if cells were 
100 % confluent). Up to 16 ml fresh DMEM medium was added and cells were incubated at 37°C again.
Storage of cell lines
All medium were removed gently from the T75 flask and washed with 10 ml 1xD-PBS (- CaCl2 and - MgCl2). The 
PBS was removed, 1 ml trypsine was added and the cells were incubated 3-4 min at 37°C. 2 ml 100% FBS sup-
plemented with 10% DMSO was added, the cells were mixed gently and the cell suspension were distributed to 2-3 
round bottom cell tubes. The cells were frozen slowly down to -80°C in a freezing box and afterwards transferred to 
a liquid nitrogen tank.
Counting and plating cells
The cell culture was split ¼ and the remaining ¾ were centrifuged 5 min (800 rpm). The medium was removed gently 
from cell pellet and 10 ml fresh DMEM was added. The cell pellet was gently dissolved and 300 µl cell suspension 
was added to 300 µl Buffer A (Chemometec) in an Eppendorf tube. The tube was vortexed 10 seconds, 300 µl Buffer 
B (Chemometec) was added and the solution was again vortexed 10 seconds. After 5-10 seconds (bobles should be 
avoided), the cell solution were pipetted with a counter-cassette (Chemometec) and cells were counted using a Nu-
cleoCounter. The cell count was multiplied by 3 for obtaining the cell suspension concentration. After counting and 
diluting the cells, 0.5 – 2x105 cells/well were plated in 6, 12 or 24 well culture vessels (Nunc) (volume of plating 2 
ml, 1 ml, 500 µl respectively). The cells were grown overnight in the cell-incubator at 37ºC, 5% CO2 and was ready 
the next day for DNA plasmid transfections using lipofectamine (Invitrogen).
Transfection of cells in culture vessels
2 µl lipofectamine 2000 was diluted in 50 µl OptiMem and resting at room temperature for 5 min. 0.8 µg plasmid 
DNA (GFP/BFP vector constructs) was diluted in 50 µl OptiMem and was mixed gently with the lipofectamine mix-
ture (total volume 100 µl). After 20 min at room temperature, the 100 µl was added to 80-95% confluent cells in one 
of the 24 cell-plate wells. After 24 hours, the cells were analysed by fluorescence microscopy (Zeiss), using blue light 
filter (BFP collecting range 370-407 nm), green light filter (GFP collecting range 447-490 nm) and red light filter (RFP 
collecting range 550-602 nm). 
Fixation of cells
Medium was removed from cells grown in a 24 well plate (Nunc) and added 500 µl 1xD-PBS (+ CaCl2 and + MgCl2) 
and resting for 2 minutes at room temperature. The liquid was removed and 100 µl 4% para-formaldehyde (PFA) was 
added on the cells and left for 10-20 min. PFA was removed and cells were washed 2x2 minutes with 500 µl 1xD-PBS 
(- CaCl2 and - MgCl2). D-PBS was removed and 750 µl MilliQ H2O added to each well. The liquid was removed and 
a 1 drop of Fluoromount G was added on the cells in each well and covered by a coverslip. The cells were stored at 
4°C in dark for later analysis by fluorescence microscopy. 
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Protein cell extraction and pull-down
Different DNA plasmids (GFP/BFP vector constructs) were transfected to COS-7 cells in separate wells (in 6 well 
plates) and after 24 hours the expressed fusion-proteins were extracted by following procedure. First, the cells were 
washed with 2 ml D-PBS and removed quickly. 1.5 ml Lysis buffer (0.5 % NP-40, protease inhibitor, 1 mM Ca2+ in 
1xTBS) was added (pipette up/down) and transferred to a 1.5 ml Eppendorf tube. The solution was centrifuged 15 min 
(4°C, 14,000g) and the supernatant protein cell extract were collected in a new tube on ice. 40 µl supernatant sample 
were mixed with 10 µl 5xSDS+DTT and stored as a control at -20°C. 500 µl of each extracted BFP fusion-proteins 
were investigated for possible interaction with GFP-GST-fusion protein (500 µl cell extract) by incubating the protein 
cell extracts overnight with agitation at 4°C. 
Next day, pull-down experiment and Western blot analysis was performed . Using primary antibody anti-GFP polyclo-
nal in 1:2,000 dilution interacting proteins could be identified by comparisons to protein extract controls.
Apoptosis cell analysis
20 hours after transfection of BFP vectors (containing C-terminal targets) to cells grown in a 24 well plate (Nunc), 
medium was removed and added 500 µl 1xD-PBS (+ CaCl2 and MgCl2). After resting for 2 minutes at room tem-
perature, the liquid was removed, 100 µl 4% PFA was added and cells were resting for 5-15 min. PFA was removed 
and the cells were washed 2x2 times with 500 µl 1xD-PBS (- CaCl2 and MgCl2). D-PBS was removed and cells were 
stained with Hoechst 33342 (5 µg/ml) for 20 min at room temperature (diluted in D-PBS -CaCl2 and MgCl2). The 
cells were washed 1x 500 µl 1xD-PBS (- CaCl2 and MgCl2), coverslips added and cells stored at 4°C until analysed 
by fluorescence microscopy. Apoptotic cells were quantified as cells demonstrating DNA fragmentation and nuclear 
condensation (Allen et al., 2001). At least 200 cells were counted in random fields using fluorescence microscopy 
(FITC filter).
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APPENDIX A - GFP & BFP vectors 
GFPs & BFP amino acid residues
The amino acid sequences between the different GFPs and BFP are highly conserved (Fig. X) and 
the proteins can heterodimerise, except for the true AcGFP monomer.
Fig. X. The GFP and BFP amino acid residues alined. The amino acid sequence of wild type (wt) green fluores-
cence protein from bioluminescent jellyfish Aequorea Victoria (Li et al., 1997; Striker et al., 1999) is alined with the 
fluorescent protein variants BFP, GFP, EGFP and AcGFP with the conserved sequence underneath (BD Biosciences, 
Clontech). 
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GFP Shuttle Vectors
The two GFP-GST shuttle vectors; p3-NLS-GFP-GST-Jun-RevNES and pS-EGFP-GST-NES-
S100A4, that were primarily used as templates for the AcGFP and NES/GST cloning. 
BFP Target Vectors 
Shown are the original pN-Max-RevM10BL-BFP (01) vector and first BFP cloning step, resulting 
in the pN-BFP-RevM10BL-BFP vector. 
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The RevM10BL amino acid sequence
Showing the NES-deficient HIV-1 RevM10BL sequence that might have some S100A4 affinity. 
Underlined is the M10 sequence characterized as a NES deficient sequence.
    1 MAGRSGDSDE ELIRTVRLIK LLYQSNPPPN PEGTRQARRN 
 RRRRWRERQR
  51 QIHSISERIL GTYLGRSAEP VPLQLPPDLR LEDLPTLDCN 
 EDCGTSGTQG
101 VGSPQILVES PTVLESGTKE NGAG
APPENDIX B - p53, MHC-IIA and liprin b1 cDNA
C-terminal cDNA of known S100A4 targets; human p53, human non-muscle myosin isoform IIA 
and human liprin b1. From the shown nucleosides, primers were designed for PCR cloning. 
 
 Human p53 C-terminal cDNA (851 bp - 1182 bp, direct)
      851 CAGAGGAAGA GAATCTCCGC AAGAAAGGGG AGCCTCACCA CGAGCTGCCC
      901 CCAGGGAGCA CTAAGCGAGC ACTGCCCAAC AACACCAGCT CCTCTCCCCA
      951 GCCAAAGAAG AAACCACTGG ATGGAGAATA TTTCACCCTT CAGATCCGTG
     1001 GGCGTGAGCG CTTCGAGATG TTCCGAGAGC TGAATGAGGC CTTGGAACTC
     1051 AAGGATGCCC AGGCTGGGAA GGAGCCAGGG GGGAGCAGGG CTCACTCCAG
     1101 CCACCTGAAG TCCAAAAAGG GTCAGTCTAC CTCCCGCCAT AAAAAACTCA
     1151 TGTTCAAGAC AGAAGGGCCT GACTCAGACT GA
 Human non-muscle myosin heavy chain IIA C-terminal cDNA (5301 bp - 5883 bp, direct)
   
     5301 CCTGGAGCGC AGCCACGCCC AGAAGAACGA GAATGCTCGG CAGCAGCTGG
     5351 AACGCCAGAA CAAGGAGCTT AAGGTCAAGC TGCAGGAGAT GGAGGGCACT
     5401 GTCAAGTCCA AGTACAAGGC CTCCATCACC GCCCTCGAGG CCAAGATTGC
     5451 ACAGCTGGAG GAGCAGCTGG ACAACGAGAC CAAGGAGCGC CAGGCAGCCT
     5501 GCAAACAGGT GCGTCGGACC GAGAAGAAGC TGAAGGATGT GCTGCTGCAG
     5551 GTGGATGACG AGCGGAGGAA CGCCGAGCAG TACAAGGACC AGGCCGACAA
     5601 GGCATCTACC CGCCTGAAGC AGCTCAAGCG GCAGCTGGAG GAGGCCGAAG
     5651 AGGAGGCCCA GCGGGCCAAC GCCTCCCGCC GGAAACTGCA GCGCGAGCTG
     5701 GAGGACGCCA CTGAGACGGC CGATGCCATG AACCGCGAAG TCAGCTCCCT
     5751 AAAGAACAAG CTCAGGCGCG GGGACCTGCC GTTTGTCGTG CCCCGCCGAA
     5801 TGGCCCGGAA AGGCGCCGGG GATGGCTCCG ACGAAGAGGT AGATGGCAAA
     5851 GCGGATGGGG CTGAGGCCAA ACCTGCCGAA TAA
 Human liprin β1 cDNA (2801 bp - 3019 bp, direct)
     2801 AAAGGATTTA AACCTGGTTT GGATATGCGC CTGTATGAGG AAGATGATTT
     2851 GGACCGGTTA GAGCAGATGG AAGATTCAGA AGGGACAGTG AGACAGATAG
     2901 GTGCATTCTC TGAAGGCATC AACAATCTGA CGCACATGTT AAAAGAAGAT
     2951 GACATGTTTA AAGATTTTGC TGCCCGTTCC CCCAGTGCCA GCATTACAGA
     3001 TGAAGACTCA AACGTTTGA
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APPENDIX C – pET151/D-TOPO expression vector
The pET151/D-TOPO vector. Used to clone PCR-directed DNA fragments in the plasmid after 
the TEV recognition site (insertion of p53 and MHC-IIA PCR fragments). The vector+insert could 
then be expressed in BL21 E. coli bacteria for protein production, induced by IPTG.
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ABBREVIATIONS & GLOSSARY
aa:  Amino acid residues
AcGFP:  Green fluorescence protein (a true monomer isoform)
Angiogenesis:  Blood vessel formations from pre-existing vessel(s)
BFP:   Blue fluorescent protein
bp:   Base pairs
BSA:  Bovine serum albumin
CKII:  Casein kinase II
Cytokine: Stimulates receptor signal transduction, mediates interactions between cells and cytokines from
  one cell type can influence other cell types.
DMEM:  Dulbeccos modified eagle medium
DMSO:  Dimethylsulfoxid
ECM:   Extracellular matrix. Consist of structural and specialised proteins and proteoglycans with 
  attached polysaccharides.
EDTA:  Ethylene diamine tetraacetic acid
EF hand motif: Ca2+ binding structure, formed by two helixes linked by a loop.
ELISA:   Enzyme linked immunosorbent assay
Endotoxins:  Frequent contaminants in plasmid DNA prepared from bacteria. Endotoxins are potentially toxic, 
  natural compounds found inside pathogens such as bacteria, which is released mainly when  
  bacteria are lysed.
ER:   Endoplasmatic reticulum
EtOH:   Ethanol
FBS:  Fetal bovine serum
FRET:  Fluorescence resonance energy transfer
FLIM:  Fluorescence lifetime imaging microscopy
FPLC:   Fast protein liquid chromatography
HRP:   Horse radish peroxidase
IPTG:   Isopropyl b-D-thiogalactopyranoside
Jun:  An oncogenic transcription factor (Knauer et al., 2005).
kb:  Kilo base pairs
LAR:   Leukocyte common Antigen-Related protein. Liprin a1 and b1 belongs to this family of trans 
  membrane tyrosine phosphatase LAR-interacting proteins. Liprin a1 interacts with transmem 
  brane phosphotyrosine phosphatase LAR and this multifunctional protein regulates several signal  
  transduction pathways including cell adhesion, cytoskeletal dynamics and b-catenin or insulin  
  signalling (Kriajevska et al., 2002).
Max:  A helix-loop-helix leucine zipper transcription factor (Knauer et al., 2005).
MetAP2: Methionine aminopeptidase 2
MHC-IIA:  non-muscle myosin heavy chain II type A
MMP:  Matrix metalloproteinase
Min.:   Minutes
NES:   Nuclear export signal
NLS:   Nuclear localization signal
NMR:  Nuclear magnetic resonance
ON:  Over night
PBS:   Phosphate buffer saline
PCR:   Poly chain reaction. Amplification of a specific DNA sequence
PKC:   Protein kinase C
p53D30:  amino acid residues 293-363 from wild type human p53
p53D37:   amino acid residues 293-356 from wild type human p53
p53D68:  amino acid residues 293-325 from wild type human p53
p53-Ala: The extreme p53 C-terminal of the amino acid residues 351-393 from wild type human p53.
RAGE:  Receptor for Advanced Glycation End products. A cell surface multi ligand receptor of the 
  immunoglobulin super family that plays an important role in diabetes, Alzheimer’s disesase, 
  inflammation and cancer (Yammani et al 2006).
ROS:  Reactive oxygen species
rpm:   Rounds per minute
RT:   Room temperature
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SDS-PAGE: Sodium dodecyl sulphate poly-acrylamide gel-electrophoresis
Si-RNA: Small interference RNA
TAE:   Tris-acetat EDTA
TBE:   Tris-boricacid EDTA
TBS-T:   Tris-buffer saline tween
TIMP:   Tissue inhibitor of metalloproteinases
Tm:   Melting temperature (of primer)
Tumor stroma: Tumor surrounding/supporting tissue of stromal and inflammatory cells, such as 
  macrophages, endothelial, fibroblasts, leukocytes, fat and mast cells.
µl:   Microliter
w.c.   Work concentration
wt:   Wildtype
X-gal:  5-bromo-4-chloro-indolyl-b-D-galactopyranoside
Abbreviations
